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External-beam radiotherapy is one of the primary methods for treating cancer. Typically 
a radiotherapy treatment course consists of radiation delivered to the patient in multiple daily 
treatment fractions over 6-8 weeks. Each fraction requires the patient to be aligned with the 
image acquired before the treatment course used in treatment planning. Unfortunately, patient 
alignment is not perfect and results in residual errors in patient setup. The standard technique for 
dealing with errors in patient setup is to expand the volume of the target by some margin to 
ensure the target receives the planned dose in the presence of setup errors.  
This work develops an alternative to margins for accommodating setup errors in the 
treatment planning process by directly including patient setup uncertainty in IMRT plan 
optimization. This probabilistic treatment planning (PTP) operates directly on the planning 
structure and develops a dose distribution robust to variations in the patient position. Two 
methods are presented. The first method includes only random setup uncertainty in the planning 
xv 
process by convolving the fluence of each beam with a Gaussian model of the distribution of 
random setup errors. The second method builds upon this by adding systematic uncertainty to 
optimization by way of a joint optimization over multiple probable patient positions.  
To assess the benefit of PTP methods, a PTP plan and a margin-based plan are developed 
for each of the 28 patients used in this study. Comparisons of plans show that PTP plans 
generally reduce the dose to normal tissues while maintaining a similar dose to the target 
structure when compared to margin-based plans. Physician assessment indicates that PTP plans 
are generally preferred over margin-based plans. PTP methods shows potential for improving 
patient outcome due to reduced complications associated with treatment. 
 1 
1 Overview 
This chapter serves as an overview of the dissertation.  
An introduction into radiation therapy is given in Chapter 2 which describes the history 
of advances in radiation therapy up to the current methods. Margin formulation and recipes are 
described along with weaknesses in margin-based approaches. Recent literature on PTP methods 
is described with the relevance to the work presented in this dissertation.  
The mathematical background of objective functions used in IMRT plan optimization is 
given in Chapter 3. The optimization proposed in this study uses dose-based and dose-volume 
based objectives and optimizes using Newton’s Method. Additionally, specific details of the 
implementation into the Pinnacle3 treatment planning are described. 
Chapter 4 describes an implementation of random setup uncertainty into treatment 
planning. This work was published (Moore et al., 2009) in Medical Physics (see Appendix I). 
Random uncertainty is implemented using fluence convolution and PTP plans are compared to 
margin-based plans. The validity of fluence convolution as an approximation of random 
uncertainty is studied for objectives in both PTP and margin-based plans. 
Chapter 5 describes an implementation of systematic setup uncertainty into treatment 
planning. This builds upon the previous chapter by adding systematic uncertainty in addition to 
random uncertainty in planning. Systematic uncertainty is implemented using a joint 
optimization over multiple probable patient positions. PTP plans are compared to optimized 
margin plans using coverage probability, dose-volume coverage maps, dose-volume coverage 
difference maps, probabilistic dose-volume histograms and physician assessment. 
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Chapter 6 describes the conclusions and potential future directions. Chapter 7 describes 
the application of portions of this research to other projects. Components of the fluence 
convolution approach were used to study the effect of clinical margins on plan quality. Plans 
developed using margin formulas were tested to determine, in a clinical case, the extent of 
uncertainty that was covered. In a separate study, additional features were used to incorporate the 
motion from a Calypso motion track into the dose distribution available in Pinnacle to compare 
treatments planned using step-and-shoot IMRT and compensator IMRT.  
 3 
2 Introduction 
In 2010, there were an estimated 1.5 million new cases of cancer in the United States 
(Jemal et al., 2010), of which external beam radiation therapy is recommended for 52% of 
patients (Delaney et al., 2005).  External beam radiotherapy involves delivering a tumoricidal 
dose of radiation to targeted cancerous tissues while attempting to minimize the dose delivered to 
normal tissues in order to reduce complications associated with treatment. This goal may be 
difficult to achieve due to (1) normal tissue located in close proximity to the targeted tissue, (2) 
inherent limitations in the physics of radiation delivery, and (3) uncertainty in the absolute 
position of the target and surrounding normal tissues during treatment. Developing methods to 
reduce the limitations associated with uncertainty in positioning is the focus of this work. 
External beam radiotherapy treatment is typically planned on a single image of the 
patient before therapy and then treatment consists of the delivery of a prescribed dose in multiple 
fractions delivered on separate days. The fractionation coupled with imperfect daily patient setup 
leads to small variations in the target position relative to the planned treatment beams. To ensure 
the target receives the prescription dose when subject to reasonable variations in position, the 
current standard of practice is to add a geometric margin around the tissues of interest and 
specify treatment objectives for the expanded volumes. This work develops and quantifies the 
ability of an alternative method, termed probabilistic treatment planning (PTP), to deliver the 
prescription dose to target structures in the presence of positional uncertainty. PTP accomplishes 
this by considering positional uncertainty during the optimization of treatment plans.  The overall 
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hypothesis of this dissertation is that PTP can improve treatment plans by reducing dose to 
normal structures while maintaining a therapeutic dose to the target as compared to margin-based 
plans. 
The remainder of the introduction describes (1) the evolution of radiation therapy 
methods, (2) margins and their formulation, (3) prior studies using PTP methods, and (4) novel 
aspects of this work.  
2.1 Evolution of radiation therapy 
External beam radiation therapy originally applied rectangular beams to treat the entire 
target volume to a prescribed dose. Since using the rectangular collimation can only produce a 
truly conformal distribution on a rectangular target, this delivered a prescription dose to the 
tumor, but resulted in the irradiation of a large volume of normal tissue near the tumor. Beam 
shaping consisted of only drawing apertures on 2-D films of the patient. 3-D Conformal 
Radiation Therapy (3DCRT) improved on this by shaping the beam to the edges of the target, 
delineated using 3D imaging, while also delivering uniform intensity for each beam resulting in a 
homogenous dose for the target. 3DCRT uses custom cut blocks or a multi-leaf collimator (MLC) 
to carefully shape the beam to the target. Blocks are a solid shape cut from a dense material to 
block radiation while a MLC contains multiple dense leaves that can move independently of each 
other to produce a shape which blocks radiation. 3DCRT reduces the volume of normal tissue 
that is exposed to radiation in the beam’s eye view. 
Intensity Modulated Radiation Therapy (IMRT) improved on 3DCRT by allowing a non-
uniform intensity of radiation for each beam. Both 3DCRT and IMRT use an MLC to shape the 
dose to the patient, however, IMRT uses the MLC to modulate the intensity of radiation 
delivered to the patient on a per-beam basis. In IMRT, plans are optimized to produce a dose 
 5 
distribution based on planning objectives which attempt to balance the need for high dose to the 
target with the need for low doses to normal tissues and/or critical structures. Various types of 
optimization objectives are used including those based upon dose, dose-volume based, effective 
uniform dose, and biological indices, with dose-volume objectives being a common method. The 
objectives used in this study are dose-volume based and are described in Chapter 3. 
2.2 Dosimetric effects of uncertainty 
Uncertainty in the absolute positions of the target and surrounding normal tissues during 
treatment with respect to the treatment delivery beams can be split into two components: random 
and systematic. Since fractionated radiotherapy occurs over a large number (~30) of treatment 
sessions, random uncertainty – the deviation of patient position from the mean patient position –
can be described as a blurring effect on the resultant cumulative dose distribution. Systematic 
uncertainty – the deviation of the mean patient position from the position used in planning due to 
setup errors being relative to a single planning image – generally results in a shift of the overall 
dose distribution from the planned location. Because of the difference in the dosimetric effects 
from each type of uncertainty, each method must be handled differently in dose evaluation. 
The dosimetric effect of random uncertainty has been modeled using convolution 
(International Commission on Radiation Units and Measurements., 1993, 1999). Two methods of 
using convolution to model random uncertainty exist: dose convolution and fluence convolution. 
Dose convolution involves convolving the computed patient dose with the distribution of random 
uncertainty.  One limitation of dose convolution is that it assumes that the dose distribution being 
convolved is shift-invariant – that is changes in position relative to the beam does not change the 
shape of the underlying dose distribution (Craig et al., 2003). Shift invariance requires that the 
underlying patient anatomy be homogenous (McCarter and Beckham, 2000). An alternative to 
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dose convolution is fluence convolution, which involves convolving the fluence of each beam 
with the distribution of setup error before dose calculation (Beckham et al., 2002). Fluence 
convolution does not assume shift invariance due to the convolution occurring before dose is 
calculated in the patient.  Validity of the fluence convolution method for a large number of 
treatment fractions (30) is shown in Chapter 4.  In this work, fluence convolution is used to 
incorporate random setup uncertainties (random only in Chapter 4 and random + systematic in 
Chapter 5) 
Systematic setup uncertainties manifest themselves as a shift in the total treatment dose 
(Baum et al., 2004). One method of assessing the dosimetric effects of systematic setup errors is 
to compute dose for multiple possible systematic shifts of the anatomy and assess dosimetric 
metrics for each shift (van Herk et al., 2002). Some studies (van Herk et al., 2002; Schwarz et al., 
2006) have simulated up to 5000 systematic errors to determine the dosimetric effect of 
systematic setup error.  In this dissertation, systematic errors are randomly sampled and used to 
simulate the dosimetric effects of systematic uncertainty. This occurs both during the PTP 
optimization, where up to 128 systematic shifts are simulated, and during the coverage-based 
plan evaluation where 919 shifts are effectively sampled. 
2.3 Margins and formulation 
Normally, the detrimental effects of patient setup positioning uncertainties are reduced by 
adding a geometric safety margin around volumes or structures which are intended to be treated 
to the prescription dose (the clinical target volume or CTV), and in some cases, margins around 
volumes or structures where dose delivery is to be avoided (the organs at risk or OARs). ICRU 
50 and 62 (International Commission on Radiation Units and Measurements., 1993, 1999) 
conceptually describes margins and the relationship to tissue structures. Components of the 
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margin definitions are shown in Figure 1. The tumor contoured by a physician is called the Gross 
Tumor Volume (GTV), which contains the volume the physician can positively identify in 
images or feel on the patient. Encapsulating this contour is a Clinical Target Volume (CTV). In 
the CTV, the regions of suspected subclinical disease are included. To account for the internal 
motion of the tumor in the patient, a margin surrounding the CTV where the tumor is presumed 
to move is termed the Internal Target Volume (ITV). Lastly, a volume to account for setup 
uncertainty of the patient is included by adding a setup margin to the ITV. This setup margin is 
chosen to be large enough that the prescribed dose will be delivered to the CTV. This final 
volume is termed the Planning Target Volume (PTV). 
 8 
 
Figure 1: Components of structure definitions and expansions according to ICRU 62. Figure used with permission from 
ICRU 62, figure 2.14 (International Commission on Radiation Units and Measurements., 1999)  
 
Physicians typically use specific treatment site protocols to specify CTV-to-PTV margins. 
Studies have been conducted to define formulas with methods for determining the extent of 
margins that should be added to the target to ensure dosimetric coverage when the effects of 
target and normal tissue positional uncertainties are considered. Van Herk has proposed a margin 
 9 
formulation designed to ensure that for 90% of patients at least 95% of the prescription dose is 
delivered to the CTV (Murshed et al., 2004; Liu et al., 2004). In simplified terms, van Herk’s 
margin formula specifies that the CTV-to-PTV margin should be  ܯ ൌ 2.5Σ ൅ 0.7ߪ where Σ is 
the standard deviation of the population systematic uncertainty (the standard deviation of the 
mean positional setup error) and ߪ is standard deviation of the population random uncertainty 
(the standard deviation about the mean for a typical patient in the population). Stroom et al. 
(Stroom et al., 1999) proposed a similar margin formula such that ܯ ൌ 2.0Σ ൅ 0.7ߪ to deliver 
95% of the prescription dose to 99% of the CTV.  
Even margins based upon uncertainty distributions result in the tissue included within the 
margins receiving a homogenous dose. Additional normal tissue is irradiated due to the fact that 
in real treatment, the treated volume, which is the volume enclosed by the prescription isodose 
line, does not strictly conform to the PTV (Murshed et al., 2004; Liu et al., 2004). Often, the 
treated volume encompasses a volume larger than the PTV resulting in an overly conservative 
estimate of the target coverage.  
As margins are the de-facto standard for accounting for positional uncertainties in 
external beam radiation therapy treatment planning, this dissertation compares plans developed 
using the PTP method with margin-based plans. Instead of using margin formulas, which would 
bias against margins, the margin is adjusted to match the coverage probability of the PTP plan 
(see Section 5.2.4.). 
2.4 Prior studies using PTP methods 
Margin-based approaches, particularly those based on margin recipes such as the van 
Herk margin formula attempt to create a robust plan by including the effects of systematic and 
random uncertainties before planning by defining the extent of the margin that would be 
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sufficient to ensure that the delivered dose to the CTV including the effects of positioning errors 
meets the prescribed treatment dose. PTP incorporates these uncertainties by considering the 
likelihood that the target will be in a specific location during treatment in the plan optimization 
process. The CTV-to-PTV expansion is not required. Instead, PTP optimizes the dose to the 
CTV (and OARs) with knowledge of the estimated setup uncertainty. Several authors 
(Unkelbach and Oelfke, 2005b, 2004, 2005a; Gordon et al., 2010; Gordon and Siebers, 2009; 
Moore et al., 2009; McShan et al., 2006; Lof et al., 1998; Witte et al., 2007; Baum et al., 2006; 
Yang et al., 2005) have reported on the potential for probabilistic methods of treatment planning, 
generally finding that  PTP has the potential to reduce dose to normal structures. Published PTP 
methods can be classified into three general categories: conceptual models, demonstration 
studies, and statistical studies. 
Conceptual models of PTP mathematically describe proposed methods for including 
uncertainty in planning (Unkelbach and Oelfke, 2004, 2005a; Lof et al., 1998). In these studies, 
simplified models of patient anatomy and uncertainty are used to demonstrate the basic 
mechanics of PTP optimization. Using a 2D circular target surrounded by a normal tissue and 
simulating a 360o arc delivery, Unkelbach and Oelfke demonstrated the potential for PTP, and 
showed that PTP can result in non-uniform fluence delivery (Unkelbach and Oelfke, 2004). In 
another work, they studied the impact of sampling a limited set of images, equal to the number of 
fractions, from probability distributions (Unkelbach and Oelfke, 2005b) and found that plans 
based on greater numbers of fractions could utilize sharper delivered dose distributions to obtain 
target coverage while those based on fewer fractions required a more blurred dose to ensure 
target coverage. The sharper distribution for greater numbers of fractions leads to higher doses in 
the target and lower doses in the surrounding tissue as the number of fractions increase. Greater 
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numbers of fractions also lead to larger standard deviations of dose at a point in the target 
volume over the 30 fraction treatment of a given patient which can be beneficial in that this 
indicates sharper dose gradients which spare more normal tissue due to more rapid decrease in 
dose outside of target structures, however, if the histogram of actual motions differs from that 
PDF assumed during planning due to the limited number of fractions (samples), dose 
inhomogeneity of a point in the target between fractions is observed. A variance reduction term 
in the objective function is required to reduce the dose inhomogeneity due to the motion, which 
reduces the peaks in the fluence profile generated when delivering an uncertainty optimized plan 
with a limited number of fractions (Unkelbach and Oelfke, 2004, 2005a). Lof et al. (Lof et al., 
1998) developed a method for including random and systematic uncertainty into an objective 
function based upon P+ (the probability of uncomplicated tumor control) which showed the 
potential to increase P+ compared to margin-based approaches on model geometries. 
There have been several demonstration studies which show the potential of PTP to 
improve plans on a small number of patients (Unkelbach and Oelfke, 2005a; McShan et al., 2006; 
Baum et al., 2006; Yang et al., 2005). These studies show on example patient cases the benefits 
of PTP methods, but lack sufficient numbers of patients to draw clinically relevant conclusions. 
For example, Birkner et al. (Birkner et al., 2003) studied re-optimized plans for 3 prostate 
patients based upon images acquired during the course of treatment. Plans are initially optimized 
with the expectation value of an EUD-based objective function over all fractions and then re-
optimized based on images acquired early in the treatment process to compensate for geometric 
variation. However, re-optimizing too early will lead to under-dosing of the target, while doing 
so too late will lead to overdosing of normal tissue due to compensating for early geometric 
variation. Increased conformality will result from re-optimized plans over margin-based plans 
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(Birkner et al., 2003). McShan et al. (McShan et al., 2006) described a  PTP method which uses 
a weighted sum of dose delivered on multiple anatomical instances during dose optimization to 
account for the dosimetric effects of random set up errors.  Their method, termed Multiple 
Instance Geometry Approximation (MIGA), uses several (7 in a clinical example) instances of 
individually shifted anatomies to account for random setup uncertainties. In an idealized 
geometry and a single clinical head and neck case, decreases in normal structure dose are 
observed compared to methods using a PTV. Also dealing strictly with random positioning errors, 
Balter et al. (Balter et al., 2005) reports that a plan generated by convolving the dose with a 
Gaussian representing the random uncertainty and adjusting the fields to maintain coverage can 
reduce the effective treatment volume by 6-8% as compared to a margin based approach. Yang et 
al. (Yang et al., 2005) reports that incorporating systematic uncertainty around targets and 
organs at risk by way of a EUD-based objective function composed of scores from a small 
number of planning scans shifted in one dimension and weighted by their probability resulted in 
greater sparing of OAR when compared to margin based approaches including methods that 
incorporate an ICRU 62 PRV (Planning Organ at Risk Volume) margin. Other groups (Gordon 
et al., 2010; Gordon and Siebers, 2008, 2009; Baum et al., 2006) have incorporated coverage 
probability calculations into the objective functions.  
Statistical studies use large patient populations and can draw statistically valid 
conclusions of the effectiveness of PTP methods.  In a study with 19 prostate patients, Witte et al. 
(Witte et al., 2007) compare PTP using an EUD-based objective function which included the 
effects of random and systematic uncertainties with margin-based simultaneous integrated boost 
plans and found a reduction of rectum toxicity by 50%. In two studies on 28 prostate patients, 
incorporating both random and systematic uncertainty by directly optimizing a plan based upon 
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coverage probability, Gordon et al. (Gordon et al., 2010; Gordon and Siebers, 2009) showed that 
a ~20% reduction of normal tissue dose could be achieved while maintaining target coverage 
probability (Gordon and Siebers, 2009) and while maintaining normal tissue dose, the target dose 
could be increased when compared to margin-based plans (Gordon et al., 2010).   
2.5 Novel aspects of the dissertation research 
The work presented in this dissertation deviates from most previous work by using a 
large number (28) of patients.  As few studies have used more than 3 patients in demonstrating 
PTP methods, this work provides a statistically valid conclusion on the benefits of PTP.  While 
previous methods of incorporating random uncertainty have used dose convolution, this work 
uses fluence convolution to incorporate random uncertainty which does not assume shift 
invariance. Systematic uncertainty in other methods has been implemented using expectation 
values in objective functions and grid-based evaluation of systematic shifts, this work uses 
independent randomly sampled systematic shifts in the analysis of the plan objective function. In 
many previous PTP studies, EUD-based objectives are used in optimization. While EUD-based 
objective functions use a biological model to estimate the effect of radiation dose, it is 
uncommon for EUD objectives to be used clinically. This work uses dose-based and DVH-based 
objectives in plan optimization which is much more common clinically.  
The method of Gordon et al. (Gordon et al., 2010)used Dose-Coverage Histograms 
directly in the objective functions which are generated by accumulating dose-volume histograms 
sampled from multiple offsets. This work uses coverage probability only in the weight 
adjustment of the OAR objectives, but not directly during optimization. To date, the published 
works of Gordon et al. have only used the CTV in probabilistic optimization in contrast to this 
work that uses probabilistic objective for both target and OARs. 
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In this work, margin-based plans with equivalent coverage probability to the PTP plan are 
generated by iteratively adjusting the margin. In general, these plans have reduced margins when 
compared to the van Herk margin formula (Gordon and Siebers, 2009). In most other studies, 
margin-based plans are developed using a margin formula, thus using coverage adjusted margin-
based plans here gives a less biased comparison of margin-based and PTP plans. Despite a more 
rigorous comparison, this study still establishes a benefit to PTP planning. 
Novel tools such as dose-volume coverage maps and dose-volume coverage difference 
maps aid in visualizing uncertainty in patient dose delivery. This study is the first to use familiar 
dose-volume plan objectives for accommodating systematic setup uncertainty. This is the first 
work to compare plans using physician preference.  
2.6 Patient alignment techniques, adaptive techniques and error reduction  
While PTP methods attempt to reduce the dosimetric consequences of patient setup errors 
by directly considering their statistical distribution during the treatment plan optimization, an 
alternative approach is to reduce the errors themselves.  This is the role of patient alignment 
techniques and adaptive radiation therapy techniques which attempt to reduce the daily random 
and patient specific systematic errors for individual patients. Alignment protocols have been 
developed to accurately position the patient before treatment. The most basic practice involves 
marking skin locations to be aligned with the lasers in the room. Other methods improve upon 
laser alignment by using portal imaging (Bel et al., 1996; de Boer and Heijmen, 2001) to align 
the patient’s bony anatomy with an image generated from the planning system. Modern methods 
for setup involve using implanted markers (Litzenberg et al., 2002), Calypso, and cone-beam 
imaging (Jaffray et al., 2002; Lattanzi et al., 1999) to align the patient immediately before 
treatment. In all of these methods, positioning error is reduced but not completely eliminated. 
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Improvement of localization and tracking may be realized in Image Guided Radiation 
Therapy (IGRT) and 4-Dimension Radiation Therapy (4DRT). IGRT involves acquiring images 
during treatment to determine where the targets are, and adjusting the patient to align the current 
setup with the planned setup. 4DRT involves tracking motion during treatment which accounts 
for large motions such as that of the lung. Studies have shown that these methods may reduce the 
margin requirements in planning (Stroom et al., 2000). These reductions, while significant, still 
leave residual uncertainty. 
Since some level of residual uncertainty seems unavoidable, methods of compensating 
for uncertainty must still be employed. Reduced margins may be achieved by adaptive planning 
techniques such as Yan et al. (Yan et al., 1998) which uses a small number (~5) daily portal 
images to adjust the beams which reduces the systematic uncertainty from 4 mm to 0.5 mm. PTP 
methods including both random and systematic uncertainty (Chapter 5) still have potential to 
reduce normal tissue doses even when only small residual uncertainties persist. Further, if 
systematic uncertainty alone can be reduced to negligible values, the remaining random 
uncertainty can be accommodated using the methods in Chapter 4. 
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3 Objective Functions 
Central to the concept of IMRT plan optimization are the objective functions used to 
generate the desired dose distribution. An objective function (sometimes termed a “cost 
function”) is a mathematical concept which describes the “costs” associated with the dose 
distribution of a given plan. Typically, the objective function is used in a minimization problem 
which aims to reduce the “cost” via modifying plan parameters to reduce the total value of the 
objective function. For intensity modulated beams, this optimization process is described in 
detail in the work of Wu and Mohan, 2000. The following description, based on their work and 
modified to clarify the calculations, is presented as it forms the basis for the optimization 
objectives described in Chapter 5. 
In computer-based optimization, the patient dose is split up into a series of volume 
elements (voxels) defined by the size of the dose grid. During dose computation, the dose to each 
volume element is calculated for each voxel. Regions of interest (ROIs) are defined via sets of 
contours which specify the voxels which are contained the target structures and organs at risk. 
The CTV, PTV and each OAR is represented by an ROI containing the respective voxels. Each 
objective function operates on the voxels contained within a single ROI. 
3.1 Dose-Based Objective Functions 
Dose-based objective functions operate by penalizing dose above (or below) the 
prescription dose. For a maximum dose objective ݂ெ௔௫஽௢௦௘, the goal is to have the dose in each 
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voxel (ܦ௜) below the prescription dose (ܦோ௫), hence voxels with dose below the prescription dose 
have no penalty, and voxels with dose above the prescription dose are penalized proportional to 
the excess squared as: 
݂ெ௔௫஽௢௦௘ ൌ 1
௥ܰ௢௜
∙ ݌ ∙ ෍ ܪሺܦ௜ െ ܦோ௫ሻሺܦ௜ െ ܦோ௫ሻଶ
ேೝ೚೔
௜
 
where ௥ܰ௢௜ is the number of voxels in the objective’s ROI, ݌ is the weight of the objective, ݅ is 
the voxel of interest, ܪ is the Heaviside function defined as  
ܪሺݔሻ ൌ ቄ1, ݔ ൐ 00, ݔ ൑ 0	, 
ܦ௜ is the dose in the ݅th voxel of the ROI, and ܦோ௫ is the prescription dose. 
For a minimum dose objective ݂ெ௜௡஽௢௦௘, the goal is to have the dose in each voxel be 
above the prescription dose. In this case, the voxels with dose above the prescription dose have 
no penalty and voxels with dose below the prescription dose are penalized proportional to the 
deficit squared. 
	݂ெ௜௡஽௢௦௘ ൌ 1
௥ܰ௢௜
∙ ݌ ∙ ෍ ܪሺܦோ௫ െ ܦ௜ሻሺܦ௜ െ ܦோ௫ሻଶ
ேೝ೚೔
௜
 
For a uniform dose objective ݂௎௡௜௙௢௥௠	, the goal is for the dose in each voxel to be a 
specific dose. In this case, the voxels are penalized proportional to the deviation from the desired 
uniform dose squared. This is actually equivalent to a combination of minimum and maximum 
dose objectives. 
݂௎௡௜௙௢௥௠		 ൌ 1
௥ܰ௢௜
∙ ݌ ∙ ෍ሺܦ௜ െ ܦோ௫ሻଶ
ேೝ೚೔
௜
ൌ ݂ெ௔௫஽௢௦௘ ൅ ݂ெ௜௡஽௢௦௘ 
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In Chapter 5, dose-based objectives are used, specifically maximum dose objectives for 
OAR structures, but primarily, dose-based objectives are the building blocks for dose-volume 
objectives. 
3.2 Dose-Volume based objectives: 
Dose-Volume based objectives operate similarly to dose-based objectives by using a 
dose-volume histogram. A dose-volume histogram displays the percentage of the volume of a 
given structure which receives greater than a specified dose. In a DVH objective, the proportion 
of voxels receiving dose above (or below) the prescription dose must be more (or less) than the 
prescription volume depending upon if it is a maximum or minimum DVH objective function. 
To accomplish this, an additional Heaviside function is added to the objective function. The 
Heaviside function uses the term	ܦ௏ೃೣ, that is the dose to the prescription volume, for the current 
dose distribution, defined as ܸ൫ܦ௏ೃೣ൯ ൌ ோܸ௫, and shown visually on a Dose-Volume Histogram 
(DVH) in Figure 2. In optimization, ܦ௏ೃೣ must be recomputed for each iteration. 
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Figure 2: Graphical representation of variables for a maximum DVH objective. The curve represents a DVH line for the 
ROI specified in the objective. ࡰࡾ࢞ is the prescription dose for the selected objective. ࢂࡾ࢞is the prescription volume for the 
selected objective. ࡰࢂࡾ࢞is the dose achieved at the prescription volume, such that ࢂ൫ࡰࢂࡾ࢞൯ ൌ ࢂࡾ࢞. The optimizer operates on 
voxels with a dose between ࡰࢂࡾ࢞ and ࡰࡾ࢞. Ideally, a completed optimization will result in ࡰࢂࡾ࢞ ൏ൌ ࡰࡾ࢞completely fulfilling the 
objective. 
 
For a maximum DVH objective ݂ெ௔௫஽௏ு, the goal is to keep the percentage of the voxels 
below the prescription dose above the prescription volume. Only voxels with dose below ܦோ௫ 
and above ܦ௏ೃೣ are penalized. Voxels with dose below the prescription dose have no penalty, as 
the dose already remains below the prescription and voxels with dose above ܦ௏ೃೣhave no penalty 
as they are in the permitted percentage of the ROI volume allowed to have dose above ܦோ௫. If 
ܦ௏ೃೣis less than or equal to ܦோ௫	then the function is zero as the objective has been fully met. 
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݂ெ௔௫஽௏ு ൌ 1
௥ܰ௢௜
ቌ݌෍ܪ൫ܦ௏ೃೣ െ ܦ௜൯ܪሺܦ௜ െ ܦோ௫ሻሺܦ௜ െ ܦோ௫ሻଶ
ேೝ೚೔
௜
ቍ 
 
 
Figure 3: Graphical representation of variables for a minimum DVH objective. The curve represents a DVH line for the ROI 
specified in the objective. ࡰࡾ࢞ is the prescription dose for the selected objective. ࢂࡾ࢞is the prescription volume for the selected 
objective. ࡰࢂࡾ࢞is the dose achieved at the prescription volume, such that ࢂ൫ࡰࢂࡾ࢞൯ ൌ ࢂࡾ࢞. The optimizer operates on voxels with 
a dose between ࡰࢂࡾ࢞ and ࡰࡾ࢞. Ideally, a completed optimization will result in ࡰࢂࡾ࢞ ൐ൌ ࡰࡾ࢞completely fulfilling the objective. 
 
For a minimum DVH objective ݂ெ௜௡஽௏ு, the goal is to keep the prescribed percentage of 
the voxels in the ROI volume receiving the prescription dose above the prescription volume. 
Only voxels with dose above ܦோ௫ and below ܦ௏ೃೣare penalized. Voxels with dose above the 
prescription dose have no penalty, as the dose already exceeds the prescription and voxels with 
dose below ܦ௏ೃೣhave no penalty as they are in the permitted percentage of the ROI volume 
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allowed to have dose below ܦோ௫. If ܦ௏ೃೣ is greater than or equal to ܦோ௫	then the function is zero 
as the objective has been met. 
݂ெ௜௡஽௏ு ൌ 1
௥ܰ௢௜
ቌ݌෍ܪ൫ܦ௜െܦ௏ೃೣ൯ܪሺܦோ௫ െ ܦ௜ሻሺܦ௜ െ ܦோ௫ሻଶ
ேೝ೚೔
௜
ቍ 
3.3 Combination of Objectives 
Any combination of the above objectives can be used within an optimization. The 
composite objective function value is then simply the sum of the individual objectives. 
݂ ൌ ෍ ௢݂
௡ை௕௝
௢
 
where ݋ is the objective of interest, ܱܾ݆݊ is the number of objectives, and ௢݂ is the objective 
function for objective ݋, e.g.	 ௢݂ெ௜௡஽௏ுor ௢݂ெ௔௫஽௏ு. 
3.4 Optimization using Newton’s Method 
To optimize using Newton’s method, the objective function is generalized as: 
݂ ൌ ෍ ܿ௜ሺܦ௜ െ ܦோ௫ሻଶ
ேೝ೚೔
௜
 
where ܿ௜ is a constant. 
The dose ܦ௜ at voxel ݅ is given by: 
ܦ௜ ൌ෍ܭ௜௝ ௝߱
௝
 
where ݆ is a ray traced from the fluence plane through the patient, ܭ௜௝ is the dose contribution of 
the ݆th ray to the ݅th voxel per unit intensity, and ௝߱ is the relative weight (or intensity) of the ݆th 
ray. 
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The intent is to optimize the weight of each fluence element, so the process computes the 
recommended change in weight ߜ ௝߱	is calculated for each ray.	 Newton’s method defines this 
change as: 
ߜ ௝߱ ൎ െ
߲݂
߲ ௝߱
߲ଶ݂
߲ ௝߱ଶ
 
Using our generalized objective function gives the first derivative: 
߲݂
߲ ௝߱ ൌ 2෍ ܿ௜ሺܦ௜ െ ܦோ௫ሻܭ௜௝
ேೝ೚೔
௜
 
and the second derivative: 
߲ଶ݂
߲ ௝߱ଶ ൌ 2෍ ܿ௜ܭ௜௝ܭ௜௝
ேೝ೚೔
௜
 
For multiple objectives, the derivatives are the sums of the individual derivatives: 
߲݂
߲ ௝߱ ൌ ෍
߲ ௢݂
߲ ௝߱
௡ை௕௝
௢
 
and 
߲ଶ݂
߲ ௝߱ଶ ൌ ෍
߲ଶ ௢݂
߲ ௝߱ଶ
௡ை௕௝
௢
 
The total weight update for a given ray first and second derivative is then  
ߜ ௝߱ ൎ െ
∑ ሺ2∑ ܿ௜ሺܦ௜ െ ܦோ௫ሻܭ௜௝ேೝ೚೔௜ ሻ௡ை௕௝௢
∑ ሺ2∑ ܿ௜ܭ௜௝ܭ௜௝ሻேೝ೚೔௜௡ை௕௝௢
 
3.5 Pinnacle Research Objectives 
The previous sections describe the theoretical methods for optimizing an IMRT plan.  
Incorporation of objective functions into a treatment planning system involves minor changes to 
 23 
the format of objective function equations but produces an equivalent result. In Chapter 5, the 
basic objective functions presented here are expanded to include the effects of systematic 
uncertainty. 
Objectives in Pinnacle are developed using the Pinnacle Research Interface using Philips 
Healthcare - Philips Radiation Oncology Systems Pinnacle3 8.1y research version. These are 
compiled codes that are used in the optimization process. The following equations are inferred 
from the example codes to relate the theoretical equations above to the functions as implemented 
in the treatment planning system. These are not specifically defined in any Philips documentation, 
but are derived here for explanatory purposes. 
In Pinnacle, each voxel of the ROI has a value ௜ܸ representing the relative volume of the 
voxel that is within the ROI. This allows Pinnacle to have partial voxels within a ROI. The sum 
of the relative volumes within an ROI is 1: 
෍ ௜ܸ
ேೃ೚೔
௜
ൌ 1 
This is used to replace the ଵேೃ೚೔ term in the objective function since 
1
ோܰ௢௜
∙ ෍ 1
ேೃ೚೔
௜
ൌ ෍ 1
ோܰ௢௜
ேೃ೚೔
௜
ൌ 1 ൌ ෍ ௜ܸ
ேೃ೚೔
௜
 
which gives a MaxDVH objective function of: 
݂ெ௔௫஽௏ு ൌ ݌ ෍ ௜ܸ ∙ ܪ൫ܦ௏ೃೣ െ ܦ௜൯ܪሺܦ௜ െ ܦோ௫ሻሺܦ௜ െ ܦோ௫ሻଶ
ேೃ೚೔
௜
 
Pinnacle also includes a scaling factor to the objective to normalize scores from different 
dose levels. This is a multiplicative constant similar to the objective weight: 
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ܵ௉௜௡௡ ൌ ൬ 1ܦோ௫൰
ଶ
 
This gives the updated Pinnacle objective function ܨெ௔௫஽௏ு: 
ܨெ௔௫஽௏ு ൌ ෍ ݌ ∙ ௜ܸ ∙ ܵ௉௜௡௡ ∙ ܪ൫ܦ௏ೃೣ െ ܦ௜൯ܪሺܦ௜ െ ܦோ௫ሻሺܦ௜ െ ܦோ௫ሻଶ
ேೃ೚೔
௜
 
The first derivative of ݂ெ௔௫஽௏ு with respect to beamlet intensity ௝߱ is: 
߲݂
߲ ௝߱ ൌ ෍ 2 ∙ ݌ ∙ ௜ܸ ∙ ܵ௉௜௡௡ ∙ ܪ൫ܦ௏ೃೣ െ ܦ௜൯ ∙ ܪሺܦ௜ െ ܦோ௫ሻ ∙ ሺܦ௜ െ ܦோ௫ሻ ∙ ܭ௜௝
ேೃ೚೔
௜
 
Since ܭ௜௝ is dependent on the beam and anatomy configuration and independent of any 
objective function, Pinnacle stores it independently of the first derivative matrix. In research 
objective functions, the independent storage removes the requirement include ܭ௜௝ in computation 
of the second derivative, thus giving the Pinnacle gradient on a per voxel basis: 
ܩ௜ெ௔௫஽௏ு ൌ 2 ∙ ݌ ∙ ௜ܸ ∙ ܵ௉௜௡௡ ∙ ܪ൫ܦ௏ೃೣ െ ܦ௜൯ ∙ ܪሺܦ௜ െ ܦோ௫ሻ ∙ ሺܦ௜ െ ܦோ௫ሻ 
where the first derivative can be obtained from 
߲݂
߲ ௝߱ ൌ ෍ ܩ௜
ெ௔௫஽௏ு ∙ ܭ௜௝
ேೃ೚೔
௜
 
The second derivative is 
߲ଶ݂
߲ ௝߱ଶ ൌ ෍ 2 ∙ ݌ ∙ ௜ܸ ∙ ܵ௉௜௡௡ ∙ ܪ൫ܦ௏ೃೣ െ ܦ௜൯ ∙ ܪ
ሺܦ௜ െ ܦோ௫ሻ ∙ ܭ௜௝ ∙ ܭ௜௝
ேೃ೚೔
௜
 
Again, Pinnacle computes ܭ௜௝ independently, giving  
࣢௜ ൌ 2 ∙ ݌ ∙ ௜ܸ ∙ ܵ௉௜௡௡ ∙ ܪ൫ܦ௏ೃೣ െ ܦ௜൯ ∙ ܪሺܦ௜ െ ܦோ௫ሻ 
where 
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߲ଶ݂
߲ ௝߱ଶ ൌ ෍ ࣢௜ ∙ ܭ௜௝ ∙ ܭ௜௝
ேೃ೚೔
௜
 
Aside from the Heaviside functions, ࣢௜ is a constant for each voxel and is treated by 
Pinnacle as a scaling value hDiagScaleFactor_. The Philips documentation for the 
Research Interface recommends for the ࣢ computation that “This method may be overloaded but 
it is seldom necessary since the default implementation should suffice for most functions.” As 
this is entirely calculated internally, the second derivative is not modified in the research 
objective functions described in Chapter 5. 
For multiple objectives in Pinnacle, the objective functions are summed, giving: 
ܨ ൌ ෍ ܨ௢
௡ை௕௝
௢
 
and the gradient: 
ܩ௜ ൌ ෍ ܩ௢,௜
௡ை௕௝
௢
 
࣢ is neglected here as it is handled internally. 
The equations described in this chapter are specifically modified to include systematic 
uncertainty in Chapter 5, however these equations are still used in Chapter 4 as the basis for 
IMRT treatment plan optimization using dose-volume based objectives. 
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4 Probabilistic planning incorporating random uncertainty 
Fraction-to-fraction deviations in patient setup positioning from the planning image result 
in a random uncertainty in patient position relative to the treatment beams. In the case of 
adaptive planning, the systematic uncertainty in patient setup position may be reduced to a small 
enough size that it can be safely ignored, leaving only random uncertainty.  Since a treatment 
course typically consists of a large number of treatment fractions (~30), random uncertainty can 
be approximated as a blurring of the fluence incident upon the patient.  A method called fluence 
convolution, is used to include random uncertainty in the planning process of this study. The 
purpose of this study is to incorporate random uncertainty into a commercial treatment planning 
system and compare the results to a margin-based approach. Standard dose-based and DVH-
based objectives are used in the optimization process. Comparison metrics include DVH analysis, 
mean dose, TCP, NTCP, and P+. Additionally, physician assessment of the resulting plans is 
compared. The concepts of this study have been published in Medical Physics and are included 
in Appendix I (Moore et al., 2009). In this chapter, the details of the study are described along 
with the process used to automate implementation. 
4.1 Methods 
Patient images and contours are acquired from 28 previously treated patients. All patient 
identifiable information is removed from these plans. Each plan is developed and optimized 
using Philips Healthcare - Philips Radiation Oncology Systems Pinnacle3 8.1w research version. 
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Beams are defined for each patient with angles of 30º, 80 º, 130 º, 180 º, 230 º, 280 º and 330 º. 
The original IMRT objectives are deleted and new objectives are defined according to the high-
dose arm of the RTOG 0126 prostate radiotherapy protocol as shown in Table 7. Direct Machine 
Parameter Optimization is used for optimization with a dose grid of 2×2×2 mm3.  
For each patient, a PTP and a margin-based plan are generated. This study assumes 
random uncertainty ߪ = 3 mm and zero systematic uncertainty (Σ ൌ 0ሻ. Random uncertainty of 
3 mm is similar to that used in other studies (van Herk et al., 2002; van Herk et al., 2000; Baum 
et al., 2004; Birkner et al., 2003; Witte et al., 2007; Craig et al., 2005). For the margin-based 
plan, the target is defined with a CTV-to-PTV margin of 2.1 mm according to the margin 
formula of van Herk et al. (van Herk, 2004; van Herk et al., 2002; van Herk et al., 2000) which 
suggests a margin of ܯ ൌ 2.5Σ ൅ 0.7ߪ. For the PTP plan, the CTV is directly used as the target 
structure. For other optimization structures, both planning methods use identical optimization 
objectives. To reduce the dose outside of the target a local normal tissue (LNT) structure is 
defined as a ring structure expanding 2 cm to 4 cm from the CTV.  
During the optimization process for PTP, the fluence is convolved at every dose 
calculation step. This process is shown in Figure 4. Fluence convolution is made possible by a 
hook into the dose calculation algorithm in Pinnacle which allows for modification of the fluence 
prior to dose calculation which is used in a Pinnacle Plugin to convolve the fluence with the PDF 
of random uncertainty. 
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Figure 4: Flowchart of Random PTP. Dose is computed by convolving the fluence with a Gaussian kernel. The objective 
function is evaluated and convergence is tested. If not converged, fluence is updated based upon the objective function 
and the process is repeated. 
The validity of convolution to approximate random uncertainty on a fixed number of 
fractions is demonstrated by simulation of multiple 30-fraction treatment courses. A total of 100 
treatment simulations are performed. The fluence of each simulated fraction is shifted by a 
random value sampled from a 3 mm Gaussian distribution. A total treatment course consists of 
the dose summed over each of the 30 fractions. Each simulated treatment course is compared to a 
treatment course generated using fluence convolution and DVH metrics are compared for each 
optimization objective using plans originally optimized with margin-based planning and PTP. 
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Comparison of each planning method is conducted using the dose-based and DVH-based 
objectives in planning. For this comparison, the final optimized fluence from both optimized 
plans is convolved with a 3 mm Gaussian to simulate the effect of random uncertainty. 
Additionally, TCP, NTCP, and P+ indices are computed for each method.  
Using the concept of a Dosimetric Margin Distribution (DMD) developed by Gordon et 
al. (Gordon and Siebers, 2008) the conformity of dose distributions for both methods is 
computed. DMD is calculated for both the CTV 90% and 50% isodose lines. Sensitivity of the 
plan to differences in estimated patient uncertainty from the actual distribution of patient setup 
errors is analyzed by doubling (σ=6 mm) and halving (σ=1.5 mm) the random uncertainty. The 
previously optimized fluence is convolved with a Gaussian of the modified uncertainty, dose is 
recomputed (not reoptimized) and DVH indices are compared.  
Physician analysis of both methods is conducted. Using the fluence convolved final dose 
distribution from each patient, DVHs of the CTV, rectum, bladder, left femur and right femur are 
produced and presented to a physician. The physician indicates which plans are acceptable for 
treatment and which plan would be preferred for each patient. 
4.1.1 Incident Fluence Interface 
The Incident Fluence Interface is a plugin into the Pinnacle TPS that allows modification 
of fluence before dose calculation. This is implemented as a hook – an executable function which 
intercepts the fluence – into the dose calculation process. If present, every time the dose 
calculation routines in Pinnacle are executed, the fluence matrix just before dose calculation is 
passed to the IncidentFluenceInterface plugin. This matrix can then be modified in place and the 
dose calculation proceeds with the updated values in the array. Pinnacle scripting commands 
defined the parameters used in the operation of the plugin.  
 30 
The plugin initially starts in the disabled state. In the disabled state, fluence is passed 
through the plugin unchanged. In the most basic of functionality, when enabled, the plugin uses 
the parameter of ConvolutionSigma to generate a 2D kernel with equal width in all dimensions 
and uses a Fast Fourier Transform to convolve the kernel with the 2D fluence matrix from each 
beam. Fixed shifts in the fluence can be accomplished by setting the parameters XShift, YShift, 
and ZShift. In order for these to apply in a 3D patient, projections of the shifts onto the 2D 
fluence matrix for each beam are calculated and a 2D shift in the fluence matrix is used. Fluence 
shifts is utilized in the study of the validity of fluence convolution. For debugging purposes, 
ability of saving and reading the fluence from a file are available and used a comparison study 
described in Chapter 7.  
4.1.2 Automation 
The entire process for generating data was implemented in a series of Pinnacle scripts. 
Pinnacle allows for scripting of most tasks in the system by generating a file with a list of 
commands to be processed sequentially. For each patient a trial with initial objectives based 
upon the RTOG-0126 protocol is defined manually (RTOG0126). This is automatically copied to 
a trial for the margin plan (Margin) and a trial for the PTP plan (PTP). The target structures for 
both plans are automatically updated. The target structure for the margin plan is PTV_2.1mm 
which is an ROI generated by expanding the CTV by 2.1 mm. The target structure for the PTP 
plan is set to the CTV itself. The margin plan is optimized from uniform beams to convergence 
with fluence convolution disabled. For the PTP plan, fluence convolution is enabled, uses a 
3 mm ConvolutionSigma, and is optimized to convergence.  
The final dose distribution for the PTP plan is from convolved beams. To compare to the 
margin-based plan, the margin trial (Margin) is copied to a new trial (Margin-Conv) and dose is 
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recomputed using fluence convolution and a 3 mm ConvolutionSigma. For both trials (PTP and 
Margin-Conv), DVHs are plotted and written to file along with the statistics (volume and 
minimum, maximum, mean and standard deviation of the dose). Biological criteria are computed 
and TCP for the CTV, and NTCP for the bladder, rectum, left and right femur, as well as P+ are 
output for the patient. The process for a single patient is entirely contained within the PTP script. 
A wrapper shell script is written external to Pinnacle which iteratively executes this script on 
each patient in the database.  
Sensitivity analysis is performed by a script which automatically convolves the final 
optimized fluence distribution with each sigma of random uncertainty (1.5 mm, 3 mm, and 
6 mm) for both trials. The DVHs, DVH statistics and biological scores are output for each sigma 
and method. 
Validation of the convolution approximation is accomplished by evaluated the delivered 
dose by simulating random interfractional motion. Simulations are computed by a plugin which 
randomly samples a 3D offset from a isotropic 3 mm Gaussian distribution. The 
IncidentFluenceInterface uses the sampled offset to shift the fluence distribution, simulating a 
fraction of treatment. The final optimized fluence for the PTP and margin based plans are used in 
simulation. For both methods, the fluence-convolved dose distribution is stored as the convolved 
dose. The plugin simulates 30 fractions of treatment, storing the dose distribution from each 
fraction and the total sum is the final dose distribution for the treatment. DVH curves for the 
CTV, rectum, bladder, left femur and right femur are output for each simulated treatment course. 
The plugin repeats this process 100 times for each method with different randomly sampled 
shifts. A shell script parses the DVH output for the dose and volume parameters of each planning 
objective. This is output as a comma-delimited file and imported into Excel for analysis.  
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4.2 Results 
Table 1 shows the dose and volume difference between simulated courses and fluence 
convolution. For margin-based plans, the average deviation of simulated treatments from the 
fluence convolved dose is less than 0.1% For PTP plans, the average deviation of simulated 
treatment from the fluence convolved dose is 0.1%. This deviation for both methods is less than 
the 2-3% variability accepted in beam delivery. 
Table 1: Minimum, maximum, range, mean, and standard deviation of DVH criteria observed over the 100 simulated 
treatment courses for the CTV and LNT structures compared with convolution. Average difference is the absolute value 
of the convolution value minus the mean of the simulated treatment courses. Simulated treatment course values are the 
difference from convolution for volumes and the percentage difference relative to convolution for doses. 
      Convolution Simulated Treatment Courses 
      Min Max Range Average Std Dev 
Margin-based CTV V7920 98.0% -0.7% 0.6% 1.3% 0.0% 0.3% 
   D98 7920 cGy -0.2% 0.2% 0.5% 0.0% 0.1% 
   V8470 0.4% -0.4% 0.8% 1.2% 0.1% 0.3% 
   D0 8506 cGy 0.0% 0.1% 0.1% 0.0% 0.0% 
  LNT V5000 1.1% -0.1% 0.1% 0.2% 0.0% 0.0% 
PTP-Based CTV V7920 97.5% -2.1% 1.0% 3.0% -0.1% 0.6% 
   D98 7890 cGy -1.8% 0.7% 2.5% -0.1% 0.5% 
   V8470 0.0% -1.6% 1.5% 3.1% 0.3% 0.6% 
   Max 8470 cGy -0.2% 0.3% 0.5% 0.1% 0.1% 
  LNT V5000 0.7% -0.1% 0.1% 0.1% 0.0% 0.0%
 
Physician review of plans indicates that the PTP-based plan is preferred in 21 out of 28 
patients. The physician indicated no preference in one plan, preferred margin in two plans, and 
rejected both plans for four patients. 
Table 2 shows the average difference in dose and volume for each objective. The average 
CTV D98 is 0.5% lower for PTP plans when compared to margin-based plans. The average CTV 
volume receiving the treatment dose for the PTP method does not differ significantly from 
margin-based plans. The volume of LNT receiving 5000 cGy is reduced by 48% using the PTP 
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method when compared to margin-based plans. All other critical structures were below the 
planning criteria.  
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Table 2: Mean, maximum, minimum, and p-value for the difference in dose and difference in volume between margin-
based and PTP-based plans for the listed objectives averaged over all patients. Plan objectives not listed were met by both 
methods for all plans. †All plans met objectives except for 2 PTP-based plans and 2 margin-based plans. ‡All plans met 
criteria except for 1 PTP-based plan. *All plans met criteria except for 1 PTP-based plan and 1 margin-based plan. 
Structure Dose (cGy) Volume Δ Dose Max Min p Δ Volume Max Min P 
Target >7920 98% -0.5% 0.6% -2.4% 0.0013 -0.4% 4.7% -3.0% 0.0916 
  <8470 2% 0.1% 1.4% -0.7% 0.1040 66.6% 780.1% -86.6% 0.4415 
Rectum <7500 15% †        
  <8470  ‡        
Bladder <8470  *        
LNT <5000  -1.9% 4.9% -10.0% 0.0095 -47.9% 50.2% -94.4% <0.0001
 
Table 3 shows the average difference in mean dose for each structure over all patients. 
Mean dose of the CTV is increased slightly using PTP when compared to margins. Mean dose to 
all critical structures is significantly reduced when compared to margin-based plans.  
Table 3: Mean, maximum and minimum difference in mean dose between margin-based and PTP-based plans, with 
associated p-values for objective structures. 
Structure Mean Δ Max Min p 
CTV 0.7% 2.0% -1.2% <0.0001 
Rectum -8.0% -1.6% -15.5% <0.0001 
Bladder -14.2% -4.5% -26.4% <0.0001 
Left Femur -11.3% -5.0% -20.6% <0.0001 
Right Femur -11.1% -3.0% -18.5% <0.0001 
LNT -12.9% -9.9% -18.2% <0.0001 
 
  
 35 
Table 4 shows the average change in TCP, NTCP, and P+ for each planning method. 
Compared to margin-based plans, PTP increases P+ by 2.5%, decreases rectum NTCP by 1.9%, 
decreases bladder NTCP by 0.7%, and decreases LNT NTCP by 0.1%. Left and right femur 
NTCP for both PTP and margin plans is zero.  
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Table 4: Mean, maximum, and minimum difference in P+, TCP, and NTCP between margin-based and PTP-based plans 
with associated p-values for objective structures 
Structure Type Mean Δ Max Min P 
All P+ 2.45% 7.60% -2.10% 0.0002 
CTV TCP 0.01% 0.30% 0.00% 0.3262 
Rectum NTCP -1.88% 2.80% -7.00% 0.0014 
Bladder NTCP -0.67% 0.00% -2.60% <0.0001 
Left Femur NTCP 0.00% 0.00% 0.00% - 
Right Femur NTCP 0.00% 0.00% 0.00% - 
LNT NTCP -0.06% 0.00% -0.40% 0.0028 
 
The dosimetric margin (Table 5) is smaller for PTP plans in 25 of 28 patients for the 
7100cGy isodose line and 27 of 28 for the 3960cGy isodose line, indicating a much more 
conformal dose distribution.  
Table 5: Dosimetric margin distributions. Mean, maximum, and minimum dosimetric margins are presented for margin 
and PTP plans for both 7100cGy and 3960cGy. A paired t-test indicates the difference between methods is significant. 
Dose 7100cGy 3960cGy 
  Mean (cm) Max (cm) Min (cm) Mean (cm) Max (cm) Min (cm) 
Margin 0.90 1.63 0.37 1.90 4.11 0.92 
PTP 0.65 1.47 0.17 1.60 3.67 0.62 
P <0.0001   <0.0001   
 
Sensitivity analysis of the mean dose (Table 6) shows that for both methods, a decrease in 
realized uncertainty from the planned uncertainty increases the mean dose for all structures 
except the LNT which shows a slight decrease. An increase in realized uncertainty from the 
planned uncertainty decreases mean dose for all structures except the LNT. Analysis of the 
objectives shows that for a doubling of the planned random uncertainty, no patients meet the 
CTV minimum dose objective for either method, but, also, none exceed the OAR objectives. For 
23 PTP plans and 10 margin plans which did not meet the CTV minimum dose, if the realized 
random uncertainty is half of the planned random uncertainty, the objective is then met.  
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Table 6: Differences in mean dose objectives when plans are subject to half (1.5 mm) and double (6 mm) the planned 
random uncertainty used in optimization. 
  Half Double 
Margin Bladder 0.3% -1.0% 
  CTV 0.2% -1.6% 
  LNT -0.4% 1.8% 
  Left Femur 0.3% -1.1% 
  Right Femur 0.4% -1.3% 
  Rectum 0.3% -1.0% 
PTP Bladder 0.1% -0.2% 
  CTV 0.4% -2.6% 
  LNT -0.3% 1.6% 
  Left Femur 0.3% -1.2% 
  Right Femur 0.4% -1.3% 
  Rectum 0.3% -1.0% 
 
 
4.3 Conclusions 
A method of incorporating random setup uncertainty into treatment planning has been 
developed. Fluence convolution used in the method is shown to be a valid approximation of the 
total dose of a fractionated radiotherapy plan. PTP-based plans maintain similar target dose to 
margin-based plans while decreasing dose to normal structures.  TCP for both methods remain 
similar, while a decrease in NTCP is observed. This results in a slight increase in overall P+. 
Physician assessment of plans generally prefers PTP plans.  
PTP Plans are sensitive to inaccuracies in the distributions of random uncertainty, 
however, this sensitivity is comparable to that of margin-based plans.  In either case, due to 
blurring, a smaller uncertainty than planned results in increased dose to structures in optimization, 
while a larger uncertainty results in decreased dose to these structures. 
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The method described in this chapter results in an reduction of normal tissue dose while 
maintaining a high dose to the target. This method removes the limitation of a CTV-to-PTV 
margin to account for random uncertainty of patient positioning in the planning process.  
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5 Probabilistic planning incorporating systematic uncertainty 
In the case that adaptive planning methods fail to reduce uncertainty in patient position below the 
necessary threshold to be ignored, plans can be optimized to reduce dosimetric consequences of 
both random and systematic patient positional uncertainty. This builds upon the previous chapter 
which included only random uncertainty. Systematic setup uncertainty is the difference in 
average patient position from the planned treatment position. Conventionally this is handled by a 
margin around the target to ensure the target receives a therapeutic dose when subject to an 
unknown systematic shift.  
 Unlike random uncertainty, systematic uncertainty cannot be described as a blurring 
effect. A systematic offset applies throughout the treatment process. The purpose of this work is 
to explicitly incorporate systematic setup uncertainty into plan optimization. This is achieved by 
joint optimization of multiple probable systematic shifts. It is hypothesized that directly 
including systematic uncertainty in planning will reduce dose to critical structures while 
maintaining a similar target coverage probability. This concepts contained within this chapter are 
described in the paper submitted to International Journal of Radiation Oncology Biology Physics 
and also in Appendix II. This chapter contains details of that work with details of the automation 
and interface developed to aid in the implementation of the proposed methods. 
 40 
5.1 Planning parameters 
For this study, imaging and contour data from 28 previously treated patients are used. 
Identifying information was removed from each data set. Patients were planned using Philips 
Healthcare - Philips Radiation Oncology Systems Pinnacle3 8.1y research version. Each patient 
has an identical 7-beam setup with beam angles of 30, 80, 130, 180, 230, 280 and 330. The 
original treatment plan was discarded and new plans were generated. Plans were optimized as 
Intensity Modulation plans. RTOG-0126 Objectives were added automatically to each plan 
according to Table 7. For PTP plans custom objective functions were used. For margin-based 
plans, the built in Pinnacle objectives were used. For all plans, a systematic uncertainty of 3mm 
was used. Random uncertainty of 3mm was implemented as fluence convolution. 
5.2 Optimization process 
The novel work of this study is to optimize while incorporating the effects of systematic 
patient setup uncertainty. The goal is to produce a plan which will deliver the same dose 
distribution to any systematic shift from the planned position sampled from the systematic 
uncertainty distribution used in planning. In order to do this, some number of systematic offsets, 
݊ܵݕݏ, are sampled from the distribution of systematic uncertainty Σ. The same objectives used in 
standard optimization are applied to the volume of each shifted anatomy which results in an 
independent objective for each shifted anatomy and effectively creates a simultaneous 
optimization over all sampled systematic shifts.  
A graphical display of this process is shown in Figure 5. The process is effectively split 
into three components: create a PTP plan, create a margin-based plan, and compare the two plans. 
Each of these steps is described below.  The process of creating a PTP plan centers around the 
objective function described below.  
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Figure 5: Overall flow of comparison process.  
5.2.1 Objective function 
The details of a standard objective function are described above and in the work of Wu 
and Mohan(Wu and Mohan, 2000). This study deviates from the typical objective functions by 
incorporating systematic uncertainty into the optimization process. This is done by a joint 
optimization of potential systematic shifts. The objective function is expanded to include an 
offset to the position of dose used in the function. For a given shift, the objective function score 
is 
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And the gradient for a given shift ݏ and a given voxel ݅: 
ܩ௢,௦,௜ ൌ 	2 ∙ ݌௢ ∙ ௜ܸ ∙ ቆ 1ܦோ௫,௢ቇ
ଶ
∙ ܪ൫ܦ௏ೃೣ,೚,௦ െ ܦ௜ା௦൯ܪ൫ܦ௜ା௦ െ ܦோ௫,௢൯൫ܦ௜ା௦ െ ܦோ௫,௢൯ 
Where ݅ ൅ ݏ represents the position of the voxel offset by the sampled systematic shift ݏ 
and ܦ௏ೃೣ,೚,௦is calculated from the DVH generated for each offset and objective. For each 
systematic shift, 	ܦ௏ೃೣ,೚,௦ has to be recomputed. 
The systematic objective functions will be computed on multiple systematic shifts. The 
total objective function for a single objective is given as the sum of the objectives for all shifts: 
ܨ௢ ൌ ෍ ܨ௢,௦
௡ௌ௬௦
௦
 
The gradient is similarly defined as: 
ܩ௢,௜ ൌ ෍ ܩ௢,௦,௜
௡ௌ௬௦
௦
 
Using the equations inferred from the Pinnacle implementation (Chapter 3), the update to 
a given intensity element is given by: 
ߜ ௝߱ ൎ െ
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Note that in the equations above, a Heaviside function dependent on ܦ௏ೃೣ,೚,௦ is used such 
as ܪ൫ܦ௏ೃೣ,೚,௦ െ ܦ௜ା௦൯. ܦ௏ೃೣ,೚,௦ is dependent on the dose distribution underlying a specific shift. 
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Generally, ܦ௏ೃೣ,೚,௦ will be different from shift to shift and thus changes the range of voxels 
affected by the optimizer.  
5.2.2 Shift List Manager 
Systematic uncertainty is incorporated into the objective function by using a series of 
multiple systematic shifts. To generate and specify the shifts used during each iteration of 
optimization, a plugin (ShiftListManager) is written to maintain the list of systematic shifts for 
optimization. Each shift is generated by randomly sampling each directional component from a 
3 mm Gaussian distribution. The number of shifts, size of the Gaussian distribution, and the 
random seed used to generate the shift are parameters of the ShiftListManager plugin. By 
specifying a random seed, a reproducible list of shifts can be generated. The same list of shifts is 
used during each iteration of optimization to ensure that the plan is robust to the list of shifts 
generated. 
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5.2.3 PTP plan generation 
 
Figure 6: PTP plan generation process. Initial RTOG-0126 objectives are loaded. Then, the initial PTP plan is generated 
by incrementally doubling the number of systematics used in optimization. Lastly, the weights of the rectum and bladder 
objectives are adjusted to produce a plan with the desired target coverage probability. 
PTP plan generation is split into three main components: define initial parameters, initial 
plan optimization and coverage-based weight adjustment. The flow of this process is described in 
Figure 6. The first step specifies the parameters used in optimization. The objectives and weights 
used here are shown in Table 7. The next step, described in more detail below, generates the 
initial plan by incrementally doubling the number of systematic shifts used in the optimization 
process until a large enough number of systematics is used in optimization. The last step, also 
described in more detail below, adjusts the OAR objective weights to produce an acceptable 
target coverage probability. The end result of the plan generation is the final PTP plan used for 
comparisons. 
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Table 7: RTOG-0126 Optimization Objectives.  
Structure 
Objective 
Type 
 
Dose Volume Weight 
Target Min DVH 7920 98 100 
Target Max DVH 8470 2 90 
Rectum Max DVH 6000 50 80 
Rectum Max DVH 6500 35 80 
Rectum Max DVH 7000 25 80 
Rectum Max DVH 7500 15 80 
Rectum Max Dose 8470 n/a 80 
Bladder Max DVH 6500 50 80 
Bladder Max DVH 7000 35 80 
Bladder Max DVH 7500 25 80 
Bladder Max DVH 8000 15 80 
Bladder Max Dose 8470 n/a 80 
Left Femur Max DVH 3500 50 20 
Left Femur Max Dose 5000 n/a 20 
Right Femur Max DVH 3500 50 20 
Right Femur Max Dose 5000 n/a 20 
Unspecified 
Tissue Max Dose 5000 n/a 0 
 
5.2.3.1 PTP Process 
The PTP process is the core of the method. This process uses multiple systematic offsets 
during the optimization process to generate a plan which incorporates systematic patient setup 
uncertainty into the optimized result. The flow of this process is shown in Figure 7. 
 46 
 
Figure 7: PTP process for incorporating systematic uncertainty into treatment planning 
The PTP process starts with an initial intensity. This intensity may be a uniform intensity 
for new optimizations, or may be a previous “guess” from a previous optimization. A better 
“guess” for initial intensity will result in a plan that converges more quickly.  
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The score and gradient array are both zeroed. Dose is calculated using the initial 
intensity. To incorporate random uncertainty, the initial fluence will be convolved with a 
Gaussian distribution before dose calculation. This process is described in the previous chapter.  
A systematic offset is selected and used to compute the objective function. The objective 
function for this systematic offset is added to the total objective function. For each voxel in the 
structure, the gradient is computed and added to the gradient array for that voxel. Afterward, a 
new systematic offset is selected and the process is repeated until all the objective function has 
been evaluated on all systematic offsets.  
The intensity is then updated using the total objective function and gradient arrays, the 
arrays are again zeroed, dose is computed and the loop is repeated until convergence. 
Convergence is defined as a change in score of less than 1E-6 or reaching 500 iterations, 
whichever occurs first. 
5.2.3.2 Initial plan optimization 
The initial plan optimization process increases the number of systematic offsets to 
produce an optimized plan. The flow of this process is shown in Figure 8. Stepping the number 
of systematic shifts in this way results in a faster optimization as the lesser numbers of 
systematic shifts produce a good starting point for the next stage of optimization without the time 
required to optimize all systematic shifts.  
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Figure 8: Initial PTP plan creation. An iterative process of increasing the number of systematic shifts is used 
incrementally doubling from 8 to 128 systematic shifts. For each number of systematic shifts, the PTP method is used to 
optimize the plan to convergence. 
The initial plan optimization starts by defining a uniform intensity over the target 
structure. Structures are specified as target structures in the initial objectives. Each intensity 
element that crosses through a voxel contained in a target structure is initially set to a uniform 
value.  
Initially the number of systematics is set to 8. The positions of each of the shifts are 
randomly generated before PTP optimization and remain fixed throughout the optimization. The 
PTP process is used to generate an initial intensity using the 8 selected systematic offsets. The 
optimized result of this is used as the initial intensity into the next step. 
After each step, the number of systematic shifts is doubled until it reaches 128. After an 
optimization using 128 systematic shifts is completed, the initial PTP plan is complete. The 
number of shifts required was studied (described in Section 5.2.6) and determined to be 
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approximately 128 shifts. Beyond 128 shifts, little improvement is observed but the time 
required greatly increases.  
5.2.3.3 Weight Adjustment 
The coverage probability of the initial PTP plan is variable from patient to patient. To 
produce a more consistent coverage probability among plans, the weights of the bladder and 
rectum objectives are adjusted to produce a higher coverage probability.  The current standard of 
practice for treatment planning using margins involves a similar step of adjusting the weights to 
produce a better trade-off between objectives. In this study, the weight is adjusted automatically 
to produce a desired coverage probability. 
 After the optimization is completed for 128 systematic shifts, the objective function 
weights are adjusted to produce a higher coverage probability of the target. This is done using a 
binary search algorithm. This process is described in Figure 9. The weights of all rectum and 
bladder constraints are adjusted with the same value. The weight of the rectum and bladder 
structures is changed, the fluence distribution from the initial PTP plan with 128 systematic 
shifts is used as a starting point, and the plan is re-optimized using the PTP method with 128 
systematic shifts. For each weight reached in the binary search, coverage probability is computed 
after optimization converges. The coverage probability calculation method is described below in 
Section 5.2.5. 
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Figure 9: Weight adjustment process for PTP. A binary search method is used to find OAR weights which produce the 
desired coverage probability. 
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The allowed range of weights for an objective is integral values from 0 to 100. A weight 
of zero indicates that the objective will be ignored during optimization. Weights are first be set to 
0 and then 100. These check the bounds of the solution space. If the desired coverage probability 
is higher than the coverage probability produced with a weight of 0, then the adjustment is 
stopped as the desired coverage probability is higher than what is achievable with this method. 
Similarly, if the desired coverage probability is less than that produced with a weight of 100, the 
adjustment is stopped as the achieved coverage probability is higher than the desired coverage 
probability for any weight specified. 
After checking the bounds of the weight adjustment, the weight is set to the middle point 
of the bounds and coverage probability is calculated. If the desired coverage probability is higher 
than the achieved coverage probability, the current weight is set to the high weight limit and this 
step is repeated. Similarly, if the desired coverage probability is lower than the achieved 
coverage probability, the current weight is set to the low weight limit. This step is repeated until 
the achieved coverage probability is within a tolerance range of the desired coverage probability, 
or the step size between weights is below the tolerance limit.  
For this study, the desired coverage probability is 95%, the tolerance range for coverage 
probability is 0.5% and the tolerance range for weight change is 1. 
5.2.4 Margin Expansion 
After the weight adjustments have been completed, a margin based plan is created. This 
plan is generated using the RTOG-0126 objectives and weights in Table 7. The CTV-to-PTV 
margin of this plan is adjusted to produce a plan with the same coverage probability as the 
weight-adjusted PTP plan. The process is visually shown in Figure 10. This is also accomplished 
using a binary search method. The target margin is first expanded by the lower bound of the 
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margin range and optimized to convergence. If the achieved coverage probability is higher than 
the desired coverage probability, margin adjustment is stopped. The target margin is then 
expanded by the upper bound of the margin range. If the achieved coverage probability is lower 
than the desired coverage probability, margin adjustment is stopped as a higher upper bound is 
required to achieve the desired coverage probability.  
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Figure 10: Process for creating optimized margin plans. A binary search algorithm is used to find a margin which gives 
similar coverage probability to a PTP plan. 
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The next margin is set to the middle point between the upper and lower bounds. The plan 
is optimized to convergence. If the achieved coverage probability is lower than the desired 
coverage probability, the lower margin limit is set to the current margin. If the achieved coverage 
probability is higher than the desired coverage probability, the higher margin limit is set to the 
current margin limit. This is repeated until the achieved coverage probability is within the 
tolerance range of the desired coverage probability or the change in margin is below the margin 
change threshold.  
For this study the desired coverage probability is set to the coverage probability achieved 
by the PTP plan, the tolerance range for coverage probability is 0.5% and the tolerance range for 
margin change is 1mm. This optimization is completed with a PRV margin of OAR+1.0cm. 
5.2.5 Comparison Metrics 
After all optimizations have been completed, coverage probability for all structures is 
computed along with Probability Dose Volume Histograms (PDVHs) and Dose Volume 
Coverage Maps (DVCMs). These are then compared for PTP and both margin methods.  
Dose volume coverage maps are generated by computing dose-volume histograms for a 
number of shifts of the dose distribution. These were calculated using a coverage data objective 
developed by Gordon et al. (Gordon et al., 2010) . In the coverage data objective, 919 shifts are 
used. These shifts are each a multiple of the dose grid resolution. A dose-volume histogram is 
generated for each shift. The area below the DVH curve is set equal to a value of 1 and the area 
above the DVH curve is set equal to a value of 0. The DVHs for all shift are then summed 
together and divided by the number of DVH curves generated and this results in a dose-volume 
coverage map. DVCMs indicate the probability that the DVH curve will be above any given 
dose-volume pair. Values of 1 indicate that the dose-volume pair will always have a DVH curve 
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above the point based upon the given systematic uncertainty. Values of 0 indicate that the dose-
volume pair will always be above the curve based upon the given systematic uncertainty. For this 
study, DVCMs were output as a binary data file with a dose resolution of 5 cGy and a volume 
resolution of 1%. DVCMs were calculated using a grid method which used steps equal to the 
size of the dose grid (2mm x 2mm x 2mm) and were imported into Matlab to produce a display 
and allow an overlay of the planning criteria for each structure. 
Dose-Volume Coverage Difference Maps are computed by subtracting one DVCM from 
another. In this study, the DVCM from the margin-based plan is subtracted from the DVCM 
from the PTP plan. DVCDMs will range in value from -1 to 1, where values below 0 represent a 
decrease in coverage probability for a dose-volume pair and values above 0 represent an increase 
in coverage probability for a dose volume pair. In order to do generate DVCDMs, the DVCMs to 
be compared are padded to be equal sizes. For padding from zero to the lower dose value on each 
map, padded values are all 1. For padding from the upper dose value on each map to the desired 
upper dose line (in this study, this is set to 100Gy) padded values are all 0. The padded array 
produced from the margin-based plan is subtracted from the padded array produced by the PTP-
based plan. The color range is then set to -1 to 1 to ensure that varying arrays can easily be 
visually compared. 
Probability Dose-Volume Histograms represent the expected DVH curve for a given 
probability. For example, the 95% PDVH indicates that 95% of the time it is expected that the 
actual DVH curve will lie above the PDVH curve. PDVHs are generated by taking the DVCM 
described above and tracing a line through the elements of the desired probability. PDVHs is 
output as a metric using the coverage data objective developed by Gordon et al. (Gordon and 
Siebers, 2009). 
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Coverage probability is the probability that a given structure will exceed a specified dose-
volume level given when subject to uncertainty. Coverage probability is calculated by shifting 
the dose distribution according to the uncertainty distribution and calculating the percentage of 
shifts that result in the specified structure exceeding a dose-volume level. Coverage probability 
values can be taken from the DVCM as a single dose-volume pair in the DVCM. Coverage 
probabilities are output as a metric using the coverage data objective developed by Gordon et al. 
(Gordon and Siebers, 2009). Coverage probability is output at each planning criteria. 
Margin and PTP plans generated in this study are also evaluated by a physician to 
determine which plans are acceptable and which plan is preferred. For physican evaluation, plans 
for each patient are randomized and labeled as A or B. PDVH and static DVH plots are presented 
to the physician to determine if a plan would be acceptable to treat and if both plans are 
acceptable, which plan would be the preferred plan to treat the patient.  
5.2.6 Determining the number of systematics 
Prior to optimization, the number of systematic shifts needed to characterize the 
uncertainty distribution is needed. To determine this value, plans are optimized using different 
random seeds. The random seed is varied from 0 to 100 in steps of 10, giving 11 different 
random seeds. Changing the random seed results in a different set of systematic shifts, which if 
insufficiently sampled will give a different coverage probability. To study the number of 
systematic shifts, each random seed is used to optimize a plan and coverage probability is 
calculated. The number of systematic shifts is doubled after each set. The standard deviation in 
coverage probability is computed for each count of systematic shifts. The process is stopped 
when the standard deviation of coverage probability for the doubled number of systematic shifts 
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is no longer significantly different from the standard deviation of coverage probability of the 
previous number of systematics.  
For the entire patient population, plans are first optimized with 16 systematic offsets 
generated with a random seed of zero (plan 16-0). The final optimized fluence from plan 16-0 is 
used as the initial fluence for an optimization with 32 systematic offsets generated with a random 
seed of zero (plan 32-0). The process is repeated for each random seed using the fluence from 
plan 16-0, and generating plan 32-10 through 32-100. Coverage probability for each of these 
plans is recorded and the standard deviation of coverage probability is calculated. Starting from 
plan 32-0, the number of systematics is increased to 64 and the process repeated.  
The process for determining the uncertainty in coverage probability for each number of 
systematics is repeated for the entire patient population and the significance of the difference in 
uncertainty in coverage probability for each systematic count is computed using a paired t-test. 
5.2.7 Automation process 
To ensure consistency in the process between patients, the entire study is automated using 
Pinnacle scripts and Tcl/Tk scripting using PinnComm. PinnComm is a communication system 
which allows an external application to query and set values within Pinnacle. The PinnComm 
library is used by a Tcl/Tk application to produce a graphical user interface (GUI) to allow for 
easily changing variables throughout the process (Figure 11). 
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Figure 11: Main GUI window for PTP with random and systematic uncertainty. 
 
At the beginning of the optimization process, all plan objectives are reset to known 
values. The original plan objectives are removed and the new plan objectives are defined. Each 
objective is defined for a single ROI. As some of the ROIs used in planning are expansions of 
the original physician contours, this process discards any expansion contours in the original plan 
and creates newly expanded contours from the base contours with a user specified expansion 
which ensures that all contours are expanded in an identical way. 
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Figure 12 shows the objective definition component of the GUI. Separate options are 
presented for loading target objectives and OAR objectives. Target objectives may be defined as 
a ‘Standard PTV’ or ‘PTP for Target’. For ‘Standard PTV’ the CTV is expanded by a user-
specified margin and the newly created PTV is set as a target objective with built-in objective 
functions. In the case of ‘PTP for Target’ the CTV is defined as the target objective and custom 
research objective functions are used. Additionally, for ‘PTP for Target’, a secondary structure 
expanded by a user defined margin set as a target objective with zero weight to ensure the 
intensity matrix will allow variation of intensity outside of the CTV. OAR objectives may be 
specified as ‘Standard OARs’, ‘OARs as PRVs’, or ‘PTP for OARs’. If ‘Standard OARs’ is 
selected, the OAR objectives are defined using the original physician OAR contours with no 
expansion and uses built in objective functions. For ‘OARs as PRVs’ the objectives are defined 
as the original OAR contours plus a user defined margin expansion and built in objective 
functions are used. The ‘PTP for OARs’ option defines the OAR objectives using the original 
physician OAR contours with no expansion, but uses custom research objective functions. 
 
Figure 12: Objective definition GUI. The GUI gives options for selecting the target and OAR objectives to be used during 
optimization. 
As each objective is independent, they must be combined to provide a total composite 
objective. The most basic composite objective is SumAll which simply sums the scores and 
gradient matrices for each objective. This is the default built-in composite objective and is used 
whenever no research objectives are used. Whenever research objective functions are used, a 
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research composite objective function must be used. This is allowed as a parameter, but in all 
cases, the research composite objective SumAllSystematic is used.  
PTP optimization requires information about the uncertainty distributions to be used in 
the optimization. For random uncertainty, a toggle option is used to determine if fluence 
convolution is to be used during optimization as shown in Figure 13. If this toggle option is 
enabled, the user specifies the sigma of the random uncertainty distribution. For simplicity of this 
study, the distribution random uncertainty is required to be Gaussian with uncertainty equal in all 
dimensions. This requirement allows random uncertainty to be implemented by convolving the 
fluence array with a 2D Gaussian of equal width in all dimensions.  This requirement may be 
relaxed by generating a 2D projection of the 3D probability density function of random 
uncertainty and convolving each beam’s fluence with the resultant kernel.  
 
Figure 13: GUI component to specify parameters of random uncertainty. A toggle box to enable convolution and specify 
the sigma of the random distribution are given. 
 
Systematic PTP requires both the distribution of systematic uncertainty and the number 
of systematic offsets to be sampled from the distribution. The GUI component shown in Figure 
14 allows for the parameters of systematic uncertainty to be specified. The sigma of the 
systematic uncertainty is required to be uniform in all dimensions, though this too can be relaxed 
and specified as independent sigmas in each dimension. The functionality to allow this is 
implemented in the underlying scripting, but is not used for this study. The user specifies a 
number of systematic offsets as well as a random seed to determine the list of systematic offsets. 
Systematic offsets are handled by a ShiftListManager plugin for this purpose. These parameters 
 61 
are passed to the ShiftListManager and a list of shifts is generated. Pseudo-random sampling is 
used to generate the list of systematic offsets. Pseudo-random sampling uses a mathematical 
function which generates numbers which appear to be random. This function uses a parameter 
called a seed which is modified each time a number is sampled. By allowing a user specified 
random seed, a reproducible set of systematic offsets can be generated, which allows for the 
entire optimization process to be reproduced. The ShiftListManager generates a list of systematic 
offsets by setting the random seed, and sampling independently the X, Y, and Z values of each 
offset. The plugin allows for the research objectives to query the number of offsets and to obtain 
the value of a selected shift. 
 
Figure 14: GUI component for systematic uncertainty. The number of shifts, random seed, and systematic sigma may be 
specified in this component. Future options of independent X,Y and Z sigmas are present but disabled in this version. 
 
Automation of the initial PTP planning (GUI component shown in Figure 15) process 
allows for varying the number of systematic offsets and random seed. A different random seed 
produces a different list of systematic shifts. Changing seeds is used to determine the required 
number of systematics. During the optimization process used elsewhere in this study, the random 
seed is zero and does not change. The number of systematics is incremented in this automation 
step by doubling the number of systematics from the starting value (16) to the maximum value 
(128) and uses the final fluence from the previous optimization as the starting fluence for each 
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successive optimization. In cases where the random seed changed, the final fluence from the 
starting random seed (zero) is used as the initial fluence in the next count of systematic offsets. 
 
Figure 15: PTP Automation  GUI. This component allows for specifying the range of nSys and random seed values. 
 
The subsections of the study are automated (Figure 16) to incrementally follow each 
other. The optimized fluence from the initial PTP optimization is used as the initial fluence for 
the weight-adjustment process. The achieved coverage probability from the weight adjustment 
process is used as a parameter into the margin adjustment process. Each of these processes is 
implemented as separate GUI components. A separate coverage GUI is designed to calculate the 
coverage probability and all output metrics. Parameters set in the coverage GUI are used each 
time coverage probability is calculated. 
 
Figure 16: Scripted optimization GUI. Each selection is followed sequentially. The desired coverage probability is 
specified for the coverage-based  weight adjustment process, and the coverage-based margin expansion process uses the 
final coverage probability from the CBWA plan. 
The coverage-based weight adjustment (CBWA) module (Figure 17) accepts parameters 
for lower and upper weight bounds (default 0-100) and a desired coverage probability (initially 
95%). Convergence criteria for the adjustment process are a minimum change in weight 
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(default=1) and the tolerance of deviation from the desired coverage probability (0.5%). When 
achieved coverage probability is compared to desired coverage probability during the binary 
search process, if the difference is less than the tolerance value, an acceptable weight is found. If 
the change in weight from one iteration to the next is less than the minimum change, the process 
stops and reports the achieved coverage probability which may have a difference greater than the 
tolerance range. If the weight used for the final achieved coverage probability is less than 1, the 
desired coverage probability is reduced by 5% and the coverage-based weight adjustment 
process is started again. As weights are specified as integral values, a weight less than 1 indicates 
an objective with zero weight which would be ignored during optimization.  
 
Figure 17: Coverage-based weight adjustment module. This GUI accepts parameters for the weight bounds and desired 
coverage probability to adjust the PTP rectum and bladder weights to produce the desired coverage probability. 
Convergence criteria of minimum change in objective weight and allowed deviation from the desired coverage probability 
are specified. 
 
The coverage-based margin expansion (CBME) module (Figure 18) uses the final 
achieved coverage probability from the CBWA module as the desired coverage probability 
during the expansion process. Like the CBWA module, the CBME module requires bounds and 
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convergence criteria. The initial upper and lower margin bounds are 0 cm to 1 cm. Convergence 
criteria are a change in margin of less than 0.05 cm or a change in coverage probability of less 
than 0.5%. The CBME module also requires the name of the ROI to be expanded – for most 
cases, the CTV – and the name of a new ROI to hold the expanded ROI. The expanded ROI is 
used as the target structure in the optimization functions.  
 
Figure 18: Coverage-based margin expansion module. This GUI accepts parameters for the CTV-to-PTV margin bounds 
and desired coverage probability. Convergence criteria of minimum change in objective weight and allowed deviation 
from the desired coverage probability are specified. 
The coverage GUI (Figure 19) specifies the parameters used in coverage probability 
calculation. The primary coverage probability metric is set which is used in the iterative 
coverage-based modules. In this study, the primary metric is the coverage probability of the CTV 
D98>7920cGy objective. Additional options to specify the dose grid size used for coverage 
probability calculation as well as the option to use fluence convolution are present. Fluence 
convolution is enabled to include random uncertainty in the coverage probability calculations. In 
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the coverage data objective developed by Gordon et al. (Gordon et al., 2010; Gordon and 
Siebers, 2009) coverage probability is calculated by shifting the dose grid by integral numbers of 
voxels. Using the optimization dose grid of 0.4×0.4×0.4 cm3 results in only 123 offsets in the 
grid-based coverage probability calculation. A dose grid of 0.2×0.2×0.2 cm3 is used during 
coverage probability calculation to increase the number of offsets to 919 in the grid-based 
calculation. Grid sizes of 0.4×0.4×0.4 cm3 are supported using the radial-based coverage 
probability calculation, but the radial-based calculation takes substantially longer to compute (~1 
hour) compared to the much faster grid-based calculation (~5 minutes). The additional metrics 
computed are specified in a list (Figure 20) which allows for coverage probability calculations, 
DVCMs, and PDVHs for each structure. This list can be saved and loaded to ensure identical 
metrics are used for all optimizations. 
 
Figure 19: Coverage calculation GUI. The metric used for coverage-based optimization is specified with the size of the 
dose grid for coverage probability calcuation.  To include random uncertainty in coverage probability calculation, fluence 
is convolved with the specified fluence convolution sigma. 
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Figure 20: Coverage metric GUI. Structures to compute coverage probability on are specified along with specific metrics 
to output including dose-volume coverage maps (dvcm), 95% probability dose-volume histogram (dvh_95) and coverage 
probability (q_98_7920 and q_2_8470).  
 
The GUI allows for saving and loading of a file containing all of the parameters for the 
entire study. Upon starting the GUI, a default parameter list can be loaded. For this study, the 
final parameter list is saved as the default parameter list. To reduce time required for 
computations, multiple patients are analyzed simultaneously. Two x86 Solaris machines with 8 
CPUs each are used for computation. Eight patients at a time on each machine are loaded and 
optimized using the default parameters in the GUI.  
After all patients are completed, PDVH curves are combined for all structures and for 
each planning method. A shell script is used to build the comparison plots for each patient using 
Xmgrace for visualization. A default parameter file was used for each patient which specifies the 
data labels, line colors, and plot dimensions. A wrapper around this script allows for the planning 
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method label to be randomized for each patient. This wrapper randomly assigns the letter A or B 
to the PTP and margin-based plan. The solid line is always used for plan A and the dashed line is 
always used for plan B. The script outputs after processing a list indicating which method is 
represented by plan A or B in order to decode the randomization for final analysis. 
DVCM and DVCDM plots are computed using MATLAB. A function is developed to 
read DVCM data and scale to a common map size. DVCDMs are generated by subtracting the 
margin-based DVCM from the PTP DVCM. All DVCM plots use a common color axis utilizing 
the full range of DVCM values (0 to 1) and DVCDM plots use the full range of DVCDM values 
(-1 to 1). An automated script is used to generate the plots for each patient, structure and method.  
5.3 Results 
The change in the standard deviation of coverage probability from 32 to 64 systematic 
offsets is 2.7%, p<0.0001. The change in the standard deviation of coverage probability from 64 
systematic offsets to 128 systematic offsets is 0.6%, p=0.16. Since the difference is no longer 
statistically significant, 128 systematic offsets is accepted as the minimum number of 
systematics required and used throughout the rest of this study. The number of systematic shifts 
may be increased past 128, but will not produce a significantly different coverage probability and 
will only increase computational time. Optimizations using 128 systematic shifts take 
approximately 8 hours. Using 256 systematic shifts, the computational time is approximately 16 
hours.  
 
5.3.1 Dose-Volume Coverage Maps (DVCM) 
DVCMs for all patients are shown in Appendix X. For the target structure, DVCMs were 
all very similar. This is expected since plans were driven to produce similar target coverage 
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probability. For all patients and planning methods, the target has 100% coverage probability until 
very close to the plan objectives and then rapidly falls off above the plan objectives. This is 
expected due to the plan objectives trying to drive a uniform dose to the target with an upper and 
lower DVH objective.  
Bladder DVCMs showed some difference between methods. PTP-based plans showed a 
higher coverage probability of the bladder at points below the optimization objectives. In all 
plans, PTP-based plans have increased coverage probability in the low dose regions. For the dose 
near the objectives, PTP-based plans show increased coverage probability up to the objective, 
but show decreased coverage probability once the dose exceeds the objective. For both PTP and 
margin-based planning, dose approaches the bladder 8470 cGy max dose constraint.  
Rectum DVCMs also showed difference between methods. Similar to the bladder, PTP 
plans showed a higher coverage probability of the rectum in the low dose regions. As the dose 
approached the objective points, PTP-based plans showed a lower coverage probability. For both 
PTP and margin-based planning, dose approaches the rectum 8470cGy max dose constraint. 
For the left and right femur, the coverage probability is very low for both planning 
methods. For the 3500cGy to <50% objective, 0% coverage probability was achieved for all 
patients, plans, and methods. For the 5000cGy max dose objective, a small tail approached the 
objective on all plans. The size of this tail is generally larger for PTP-based plans than margin-
based plans. For the left femur the tail reached the objective on 21 out of 28 plans for PTP-based 
planning, and 12 out of 28 plans for margin-based planning. For the right femur the tail reached 
the objective on 22 out of 28 plans for PTP-based planning, and 12 out of 28 plans for margin-
based planning.  
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5.3.2 Dose-Volume Coverage Difference Maps (DVCDMs) 
Target DVCDMs show a very small band of coverage change which would be well below the 
difference caused by any uncertainty in dose. This is expected due to the goal of matching plan 
coverage. 
DVCDMs look significantly different for the OARs. Without any objective to increase 
dose, the coverage varies below the objectives. For these DVCDMs we define 3 regions as 
shown in Figure 21: Region A is the region completely below the plan objectives, Region B is 
the region completely above the plan objectives, and Region C is the region near the plan 
objectives. Coverage differences in Region A are unimportant as it is below the plan objectives 
and the optimizer has no objective to drive the dose down in these areas. Coverage differences in 
Region B are important as this is where the optimizer failed to reduce the dose below the plan 
objectives. Coverage in Region C shows the objective tradeoff as the optimizer finds a solution.  
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Figure 21: Regions of a DVCM. Region A is below plan objectives, Region B is above plan objectives and Region C is near 
plan objectives. 
For the bladder DVCDM, PTP-based plans show an increased coverage in Region A. For 
Region B, some plans show a slight reduction in coverage, but generally both plans have no 
coverage in this region. For region C, there is no noticeable trend in coverage change. Some 
PTP-based plans have higher and others have lower coverage. 
For the rectum DVCMs, PTP-based plans show an increased coverage in Region A. For 
Region B, PTP-based plans generally show a reduction in coverage, though for some patients, 
both plans are below criteria. For Region C, PTP-based plans generally show a reduction in 
coverage, though for some patients some slight increases occur.  
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For the left and right femur, all PTP-based plans show an increase in coverage. This is 
predominantly in Region A where both plans are substantially below the plan criteria. Some 
increase in coverage is noted in Region C as a tradeoff for lower dose in other structures. Neither 
plan has coverage in Region B.  
5.3.3 Coverage Probability 
 Target coverage probability is generally the same for each patient due to the design of the 
study. On average the coverage probability achieved by PTP-based plans is 90% +/- 5% and the 
average coverage probability for margin-based plans is 91% +/- 5%.  A paired t-test indicates 
that this is not significant (p=0.1697). For the margin-based plan, the average margin required to 
match the PTP plan is 0.6 cm.  
When compared to margin-based plans, PTP plans reduced the average coverage 
probability for the rectum D35=65Gy objective by 17% (p=0.010), 23% for the D25=70Gy 
(p=0.0001), and 27% for the D15=75Gy objective (p<0.0001). The average coverage probability 
of the bladder increased 2% for the D50=65Gy objective (p=0.0005), increased 3% for the 
D35=70Gy objective (p=0.0157), decreased 6% for the D15=80Gy objective (p=0.0146). Left 
femur coverage probability increased 4% for the Dmax=50Gy objective (p=0.0078) and the right 
femur increased 6% for the Dmax=50Gy objective (p=0.0024). None of the other objectives 
showed significant changes. 
5.3.4 Probability Dose-Volume Histograms (PDVH) 
Target PDVH curves were very similar between both methods. Again, this is expected 
since the both plans were driven to produce the same target coverage probability. PDVHs for all 
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patients are shown in Appendix X. For both methods, the PDVH curve is 100% until nearly the 
D98 objective after which the dose drops off sharply to D2 objective. 
For OAR structures, PDVHs tend to show that PTP plans have higher volumes receiving 
dose below the plan objectives and lower volumes receiving dose above the plan objectives. The 
rectum specifically shows a noticeable decrease in volume near the planning objectives for the 
PTP plans. The bladder shows a higher overall volume receiving dose but is generally below the 
objectives for both plans. PTP shows higher volumes receiving dose for both left and right femur, 
but this is well below the plan objectives for both methods. 
5.3.5 Physician Assessment  
Plots were generated to be presented for physician assessment. The process of generated 
these plots involved the output of Probability Dose-Volume Histograms and static Dose-Volume 
Histograms from the treatment planning system. Before presenting these to the physician, the 
plans are randomized to remove any bias from the assessment. Randomly, plans for each patient 
were assigned a letter of A or B. On the plots, curves from plan A are displayed as a solid line 
while curves from plan B are displayed as a dashed line. Curves were generated and displayed 
for the CTV, bladder, rectum, left femur and right femur structures. Additionally, markers were 
placed on the graph to indicate the planning objectives used during optimization. A single plot 
was produced for each patient for both PDVHs and static DVHs.  
Initially, Probability Dose-Volume Histograms (PDVHs) were presented to a physician. 
The initial response was that none of the plans from either method was acceptable. After further 
discussion with the physician, it was determined that plans were deemed unsatisfactory due to a 
high rectal dose on the majority of plans. The RTOG-0126 protocol allows for rectal dose to 
reach these limits, but this conflicted with the physician’s personal protocol for prostate 
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radiotherapy. Additionally, since PDVHs show a greater dose to critical structures, the plan was 
further from acceptable limits. The physician was then asked to choose which plan would be 
preferred if a choice had to be made. Using the PDVHs, the physician would choose the PTP 
plan over the margin plan for 21 patients and would prefer the margin plan for 7 patients. 
The physician was then presented with static DVH plots. For these plots, it was assumed 
that there was no margin on the critical structures (PRV = OAR) and the PTV expansion was 
CTV+0.3 cm posteriorly and CTV+0.7 cm in all other directions. These values match the 
prostate IMRT protocol used by the protocol typically used by that physician. Static DVHs were 
generated using these structures, but planning and optimization was not repeated. Using these 
definitions, the physician again found the majority of plans to be unacceptable. After discussions, 
the physician selected the preferred plan even if neither was acceptable. The PTP plan was 
chosen for 25 patients while the margin plan was chosen for 3 patients. 
An additional physician was sought that uses the RTOG-0126 protocol on a regular basis. 
This physician reviewed the plans using the same static DVHs presented to the first physician 
and reported that the PTP plan is preferred for 24 patients while the margin is preferred for 4 
patients. For 23 patients, both physicians preferred the PTP plan. For 2 patients, both physicians 
preferred the margin-based plan. For 3 patients, there was not a consensus on the preferred plan. 
5.4 Discussion 
In the plan assessment stage, both static DVHs and PDVHs were used. It is believed that 
PDVHs present a more realistic view of plan quality. In a static DVH, the curves indicate the 
dose delivered in a single idealized patient setup. To incorporate uncertainty into the static 
DVHs, the physician looks at a curve representing the PTV as representative of the CTV under 
uncertainty while the critical structures are only displayed in a purely static idealized case. In a 
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PDVH, the curves represent the expected DVH for a specified coverage probability. For the 
curves demonstrated in this work, the probability of CTV doses exceeding the PDVH is 95% and 
the probability of the dose to the critical structures being lower than the PDVH is 95%. 
Therefore, it is expected that in 95% of cases, the plan will perform better than the displayed 
curves.  
Use of PDVHs in physician approval of plans will incorporate uncertainty into the 
decision making process. This may initially raise concerns as the dose displayed for critical 
structures is typically much greater than displayed on a static DVH, however, these curves are 
generated from the same underlying dose distribution.  
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For two patients (Patients 13 & 15) visual artifacts were observed in the DVCMs. These 
visual artifacts appeared as “squiggles” in the data as shown in Figure 22. This was determined 
to be a result of low resolution calculation of the DVCMs. The original DVCM data for this 
study was computed using a grid method which used rigid shifts in the dose grid to compute 
coverage probability. This produced a very fast calculation (~5 min) but sampling was restricted 
to the size and dimensions of the dose grid. An alternate method of calculating this is radial 
mode. In this mode, samples are chosen radially (In this study, at 10 degree increments) and at a 
given step along each ray (0.5mm). This method takes much longer (~2 hours) but produces a 
much smoother result similar to Figure 23. Graphically these results appear fairly different, 
however, when looking at the difference between the two shown in Figure 24, the differences are 
relatively small. 
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Figure 22: DVCM "Squiggles". These are produced due to the size of the dose grid used to calculate coverage probability 
in grid mode.  
 77 
 
Figure 23: Smoothed DVCM using radial mode. In radial mode, the distribution of coverage probability values is sampled 
more accurately at the cost of significant computational time. The smoothed DVCM shows an image with less stepped 
transitions between coverage levels. 
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Figure 24: Difference between DVCM computation modes 
Pinnacle loads every trial into memory when the plan is loaded. These trials stay loaded 
in memory until Pinnacle is closed. This is normally not of any concern, however, when a large 
number of trials are maintained in a Pinnacle session, the memory overhead becomes very large. 
A single trial loaded into Pinnacle may only require on the order of 300MB, but when more than 
10 trials are kept in memory, the 32-bit memory limit of approximately 4GB is exceeded.  
In this study, random sampling from a Gaussian PDF is used. It is assumed that with a 
sufficient number of samples, the distribution will be well characterized. In the case of large 
numbers, each random sample has equal weight as less likely samples should occur less 
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frequently. Alternatives to this are quasi-random sampling and weighted sampling. Quasi-
random sampling attempts to more uniformly sample the distribution to better characterize it 
with fewer samples. Quasi-random samples, like random samples, have equal weight. Weighted 
sampling (similar to MIGA) chooses a number of fixed offsets and assigns a weight to each 
based upon their likelihood. In weighted sampling, samples close to the expected value will have 
higher weights, while samples further from the expected value will have reduced weights. 
In several cases, it was noted that the ROIs for the OARs overlapped the CTV ROI. In 
these cases, a conflict for objectives was observed. To resolve objective conflicts, the OARs 
were redefined as the original OAR with the target volume excluded. This was achieved in 
Pinnacle by expanding by a zero margin an ROI with the OAR as the source and excluding the 
interior of the target. 
5.4.1 Other Attempted Methods 
The original attempt at implementing systematic uncertainty into treatment planning 
involved using an external application linked to Pinnacle via scripting. This external application 
used scripts to obtain the patient anatomy, compensator matrix, and beam configuration. Using 
this information, objectives were defined for optimization. These objectives were limited to 
dose-based and dose-volume based objectives.  
The method used for optimization in the external application involved directly modifying 
the fluence matrix. A flow chart describing this method is shown in Figure 25. For each sampled 
offset, the plan was optimized for a single iteration. After all offsets are optimized, the fluence 
was averaged to produce the updated fluence. This fluence was again optimized for a single 
iteration for each offset, and the process was repeated until convergence. The basic function of 
this is 
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This method was eventually abandoned due to difficulties in modification of the original 
external IMRT optimizer. The most prevalent of issues being that the state of the intensity and 
dose matrices were not consistently maintained throughout code execution. While for a static 
optimization, this had no effect, when attempting to update the intensity, the incorrect matrices 
led to incorrect updates to the fluence. Additionally, this external code was originally written 
before plugins had been developed for Pinnacle. Directly interfacing with a clinically approved 
treatment planning system allows for a more reliable solution without recreating an existing 
implementation. 
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Figure 25: Direct fluence PTP 
Later, this method was incorporated into a Pinnacle plugin. Unfortunately, due to the 
intense computational requirements (approximately 2 weeks per patient), this too was abandoned 
in search of a less time consuming method.  
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5.5 Conclusions 
This chapter describes the implementation a method for including random and systematic 
patient setup uncertainty into the treatment planning process. Generally, PTP results in a 
decrease in dose to normal tissues (especially the rectum) while maintaining the same coverage 
probability for the target when compared to margin-based plans. Physician assessment indicates 
preference of PTP plans due to the ability to reduce rectal dose. PTP may result in the ability to 
remove CTV-to-PTV margins and optimize directly on the CTV.  
New methods of plan analysis are presented in this study. The use of DVCMs and 
DVCDMs as an assessment and comparison metric allows for visual display of the effects of 
uncertainty on a treatment plan. Physician assessment of plans allows for demonstration of 
clinical feasibility of treatment plans generated using PTP.  
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6 Conclusions and future directions 
Methods for incorporating random and systematic uncertainty into treatment planning 
using PTP have been implemented and tested using a commercial treatment planning system. 
Each method presented in this dissertation shows the ability to reduce normal tissue dose while 
maintaining a therapeutic dose of radiation to the target. For both methods, plans producing 
similar target coverage probability have been developed using a margin-based approach for 
comparison. These methods have potential to remove the need for a CTV-to-PTV margin in 
treatment planning. 
For random only PTP plans, PTP and margin plans both show similar dose to the target 
structure, though PTP plans tend to have a slightly lower dose to the target structure. Compared 
to margin-based plans, PTP plans show a significant decrease in dose to the local normal tissue 
structure. Mean dose for OARs is decreased using PTP methods. Compared to margin-based 
plans, PTP plans have similar TCP but a lower NTCP for critical structures resulting in an 
overall increase in P+.  
Physician assessment of margin-based and random-only PTP plans shows that for 75% of 
patients, PTP plans are preferred over margin-based plans. For 7% of the patients, the margin-
based plan is preferred and no plan is preferred for 18% of patients. 
For PTP including both random and systematic uncertainty, PTP and optimized margin 
plans produce similar target coverage probability. PTP plans can be generated which meet a 
specified coverage probability goal and margin-based plans can be optimized to meet similar 
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achieved coverage probability. Compared to margin-based plans, PTP plans reduce the coverage 
probability of high dose rectal objectives. PTP plans generally show a decrease in coverage 
probability near the plan objectives while increasing dose in unconstrained regions. 
Physician assessment of PTP plans generated using random and systematic uncertainty 
indicates that PTP plans are generally preferred. For 71% of patients, PTP plans are preferred 
over margin-based plans. Margin-based plans are preferred for 7% of patients, while physicians 
indicate mixed preference for 21% of patients. 
The work presented here approximates both random and systematic uncertainty 
distributions as isotropic Gaussian distributions. The framework is largely in place to relax this 
restriction. Random uncertainty is implemented via convolution of a 2D Gaussian kernel with the 
2D fluence matrix of each beam. An arbitrary 3D distribution of uncertainty may be used by 
generating a 3D kernel from the distribution and projecting it on the 2D plane of the fluence 
matrix. Systematic uncertainties are handled by generating a list of shifts. These shifts are 
currently generated by sampling a shift in each dimension from a 1D Gaussian distribution of 
equal width for each dimension. This can be trivially relaxed by allowing a different width of the 
Gaussian distribution for each dimension. A process for doing this is already implemented in the 
ShiftListManager but isotropic Gaussian distributions are used here for simplicity. This can be 
further relaxed by allowing sampling from any specified distribution. Rigid shifts in patient setup 
position are used in this study, but future studies may extend this to the use of deformed anatomy. 
In the case of deformed anatomy, multiple patient images can be used instead of rigid systematic 
shifts.  
In the current implementation, optimization incorporating systematic uncertainty requires 
substantial computational time. Fortunately, the optimization method here is easily parallelized. 
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If multiple computers (or CPUs) are available, the processing of systematic shifts can be split 
such that a portion of the processing is done on several independent CPUs. Splitting of the 
calculations is possible since the computation of each individual systematic shift is independent 
of other systematic shifts. In theory, using twice as many CPUs should result in half the 
computational time (ignoring overhead). Allowing the process to use as many CPUs as the 
number of systematic shifts used in optimization should result in the optimization requiring the 
same amount of time as a standard optimization. 
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7 Extensions to other projects 
Many software modules have been described in this dissertation. Each of these software 
modules were developed to further the study described. Fortunately, these modules also have use 
in other studies conducted at this university. This chapter briefly describes two specific projects 
which used components of the software developed for this work.  
A plugin which modifies the fluence during dose calculation is used in the studies 
described in the chapters above. The primary use in the chapters above is to convolve the fluence 
with the random uncertainty distribution during IMRT optimization. A similar implementation, 
prior to the Pinnacle hook to modify the fluence distribution, is to convolve the intensity matrix 
with a Gaussian distribution. Unfortunately, the intensity convolution method requires slight 
adjustments to the width of the jaws to account for the widening of the fluence distribution. The 
intensity convolution method is used in Gordon et al. (Gordon et al., 2007) to simulate the effect 
of random and systematic setup errors on the dose distribution and compare to margin formulas. 
Gordon’s study of 27 patients convolved the intensity matrix to include random uncertainty in 
simulation and used 50 simulated systematic shifts to include systematic uncertainty. The results 
generally show that margin formulas are pessimistic and smaller margins can be used (Gordon et 
al., 2007). 
The IncidentFluenceInterface can additionally be used to input arbitrary fluence matrices into the 
dose calculation process. The ability to save and load fluences in the plugin allows for 
modification of the fluence outside of Pinnacle. In the study by Waghorn et al. (Waghorn et al., 
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2010) the IncidentFluenceInterface plugin is used to export the fluence for each beam to a file. 
The file is used as a parameter into Matlab code executed on a different computer which adapts 
the fluence to the motion tracks generated by Calypso – an implanted seed-based localization 
system. The adapted fluence is then loaded into Pinnacle for dose calculation. The study shows 
with a Gamma pass rate of 98.3% +/- 0.7% that the motion-encoded fluence maps agree well 
with film measurement of the Calypso tracks.  
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The purpose of this study is to incorporate the dosimetric effect of random patient positioning
uncertainties directly into a commercial treatment planning system’s IMRT plan optimization algo-
rithm through probabilistic treatment planning PTP and compare coverage of this method with
margin-based planning. In this work, PTP eliminates explicit margins and optimizes directly on the
estimated integral treatment dose to determine optimal patient dose in the presence of setup uncer-
tainties. Twenty-eight prostate patient plans adhering to the RTOG-0126 criteria are optimized
using both margin-based and PTP methods. Only random errors are considered. For margin-based
plans, the planning target volume is created by expanding the clinical target volume CTV by
2.1 mm to accommodate the simulated 3 mm random setup uncertainty. Random setup uncertainties
are incorporated into IMRT dose evaluation by convolving each beam’s incident fluence with a
=3 mm Gaussian prior to dose calculation. PTP optimization uses the convolved fluence to
estimate dose to ensure CTV coverage during plan optimization. PTP-based plans are compared to
margin-based plans with equal CTV coverage in the presence of setup errors based on dose-volume
metrics. The sensitivity of the optimized plans to patient-specific setup uncertainty variations is
assessed by evaluating dose metrics for dose distributions corresponding to halving and doubling of
the random setup uncertainty used in the optimization. Margin-based and PTP-based plans show
similar target coverage. A physician review shows that PTP is preferred for 21 patients, margin-
based plans are preferred in 2 patients, no preference is expressed for 1 patient, and both autoge-
nerated plans are rejected for 4 patients. For the PTP-based plans, the average CTV receiving the
prescription dose decreases by 0.5%, while the mean dose to the CTV increases by 0.7%. The CTV
tumor control probability TCP is the same for both methods with the exception of one case in
which PTP gave a slightly higher TCP. For critical structures that do not meet the optimization
criteria, PTP shows a decrease in the volume receiving the maximum specified dose. PTP reduces
local normal tissue volumes receiving the maximum dose on average by 48%. PTP results in lower
mean dose to all critical structures for all plans. PTP results in a 2.5% increase in the probability of
uncomplicated control P+, along with a 1.9% reduction in rectum normal tissue complication
probability NTCP, and a 0.7% reduction in bladder NTCP. PTP-based plans show improved
conformality as compared with margin-based plans with an average PTP-based dosimetric margin
at 7100 cGy of 0.65 cm compared with the margin-based 0.90 cm and a PTP-based dosimetric
margin at 3960 cGy of 1.60 cm compared with the margin-based 1.90 cm. PTP-based plans
show similar sensitivity to variations of the uncertainty during treatment from the uncertainty used
in planning as compared to margin-based plans. For equal target coverage, when compared to
margin-based plans, PTP results in equal or lower doses to normal structures. PTP results in more
conformal plans than margin-based plans and shows similar sensitivity to variations in
uncertainty. © 2009 American Association of Physicists in Medicine. DOI: 10.1118/1.3176940
Key words: IMRT, probabilistic planning, robust treatment, uncertainty
I. INTRODUCTION
In external beam radiation therapy, the current method of
compensating for patient positioning uncertainties is to apply
margins around the contoured patient structures.1,2 Treatment
dose levels are planned to be delivered to the margin-
expanded region around the target while doses are limited
within the margin-expanded regions around critical struc-
tures. Margins are intended to ensure that the target is cov-
ered when subject to “reasonable” random and systematic
patient position variations and that critical structures are
similarly spared when subject to such variations. If the clini-
cal target volume CTV margin is insufficient, the CTV can
move outside of the expected treatment region resulting in
underdosing of the target and poor tumor control. Similarly,
if a planning organ at risk volume PRV margin is insuffi-
cient, normal tissue and critical structures can move into re-
gions receiving treatment dose levels resulting in unnecessar-
ily high doses to these structures, which may result in greater
complications. The addition of a margin reduces the likeli-
hood of the target being outside of the treatment region;
however, this also increases the likelihood that normal tissue
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or critical structures will fall within the treatment dose re-
gion. In order to meet the goals of margin-based planning,
formulas have been created to determine the size of suitable
margins.3,4 An example is the margin formula of van Herk et
al.,4–6 which specifically aims for 90% of patients to receive
95% of the prescribed treatment dose.
Patient treatment involves many sources of positioning
uncertainty. Random uncertainty stems from daily changes in
patient positioning and patient anatomy. Systematic uncer-
tainty represents a shift from the mean of the expected pa-
tient position. Random uncertainty results in a blurring of the
dose distribution. Systematic uncertainty results in an un-
known shift in the dose distribution. Given these differences,
the methods of including the effects of these uncertainties
into the dose distribution differ. Random uncertainties can be
compensated for by multiple sampling of the patient position
or by convolution. Systematic uncertainties do not lend
themselves to convolution-based solutions. Fortunately,
modern advances in image guidance have decreased the sys-
tematic and random uncertainties present in radiation
therapy. Implanted markers, portal image-based setup, and
cone-beam CT are just a few of the methods that show po-
tential to decrease setup errors.7–12 Systematic uncertainties
can be significantly reduced using repeated imaging adaptive
setup protocols such as those used by Yan et al. and Hooge-
man et al. that indicate that use of four to six initial portal or
CT images can estimate and effectively reduce systematic
setup errors.13,14 While adaptive setup protocols can signifi-
cantly decrease systematic uncertainty, random uncertainties
are less effectively reduced using these methods.14
In IMRT planning, the margin-expanded planning target
volume PTV acts as a surrogate for the CTV, the actual
position of which varies from fraction to fraction. With the
patient setup uncertainty added over several treatment frac-
tions, ensuring coverage or sparing of the margin-expanded
volume should ensure coverage or sparing of the underlying
structure of interest. In margin-based planning, the dose dis-
tribution of the expanded structure is intended to be repre-
sentative of the underlying structure when expected setup
uncertainties are considered.4 However, with knowledge of
the setup uncertainty and tissue motion distributions, the
PTV surrogate can be removed and planning can be done
directly on the CTV. Probabilistic treatment planning PTP
attempts to ensure coverage of the target without addition of
explicit margins by incorporating an uncertainty model di-
rectly into the plan optimization process. Several authors
have studied PTP.15–31 The general finding of these studies is
that PTP reduces normal tissue and organ at risk OAR
doses while maintaining the same target coverage as margin-
based plans.
The purpose of this study is to implement a method of
incorporating random uncertainty into treatment planning
and to compare this method with margin-based planning.
Plans are generated using standard dose-volume histogram
DVH-based criteria for prostate planning on a large popu-
lation of patients including many structures with criteria de-
fined in RTOG0126. The simplicity of the proposed method
allows for arbitrary optimization objective functions to be
defined in the treatment planning system TPS. Comparison
metrics include DVH analysis, mean dose, tumor control
probability TCP, normal tissue complication probability
NTCP, and coverage probability. Systematic errors are not
considered within this optimization. It is assumed that sys-
tematic errors are substantially reduced by application of an
adaptive therapy protocol,14 and any remaining systematic
uncertainty in a structure’s position is incorporated into the
structure contours. Fluence convolution is used to approxi-
mate the effects of random patient setup errors over multiple
fractions of dose delivery. The validity of the fluence convo-
lution assumption is tested by sampling different possible
treatment scenarios. The sensitivity of the optimized result to
changes in the patient’s random setup uncertainty from that
applied within the optimization is also studied.
This paper deviates from previous PTP work in that it
uses existing objective functions directly within the commer-
cial TPS. Additionally, fluence convolution is used to simu-
late the effect of random errors instead of dose convolution
during the plan optimization, typical DVH-based objective
functions are used instead of custom TCP-based objective
functions, and a large patient population is used to demon-
strate statistical significance of the similarity in dose cover-
age for the CTV and the dose reduction to normal tissues for
PTP. This study compares PTP to margin-based planning,
showing differences using the DVH metrics used in optimi-
zation. Models for P+, TCP, and NTCP are used to compare
plan quality. Dosimetric margins are computed for both
methods to evaluate conformality changes between methods.
Finally, sensitivity analysis is conducted to verify that PTP is
not highly sensitive to inaccuracies in the patient uncertainty
distribution estimate.
II. MATERIALS AND METHODS
Patient imaging data and structure contours used in this
study are derived from 28 in-house prostate patients. In ac-
cordance with our institutional review board protocol, all pa-
tient identifiable information is stripped from each data set
prior to use in the study. Since this study employs a paired
comparison between two planning methods that are unrelated
to the treatment plans used for the actual patient treatments,
the plans that were used for patient treatment are deleted.
Additional structure contours are added as needed.
For each patient image set, IMRT treatment plans are de-
veloped using Philips Medical Systems Pinnacle3 8.1w re-
search version Philips Medical Systems, Fitchburg, WI.
The research version allows for the in-house code to be in-
corporated into the planning system by way of plugins. Dose
is calculated using the adaptive convolution algorithm with a
dose grid of 222 mm3. The IMRT plans are optimized
with direct machine parameter optimization DMPO. Each
patient is planned with seven beam angles of 30°, 80°, 130°,
180°, 230°, 280°, and 330° in IEC coordinates. Patients are
each planned according to criteria specified by RTOG0126,
an external beam radiation therapy prostate carcinoma dose
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escalation protocol. The plan optimization criteria are shown
in Table I. Each virtual patient is planned to be delivered
over a course of 30 treatment fractions.
Two planning approaches are used, traditional margin-
based planning and PTP. For margin-based planning, a PTV
is created using a 2.1 mm margin around the CTV. This is in
accordance with the margin formula of van Herk et al.4–6
which recommends a margin of M =2.5+0.7. With
an assumed random uncertainty of =3 mm and no system-
atic uncertainty =0, the recommended margin is
M =2.50+0.73=2.1 mm.
The 3 mm random setup uncertainty is representative of
those used in related literature4,6,15,17,30,32 and is consistent
with, though somewhat larger than, what is observed in in-
house internal marker-based daily alignment protocol. Re-
ported random setup uncertainty values have significant
variation, ranging from 0.9 to 5.1 mm. We believe that the
exact value for the assumed random uncertainty is not re-
quired for the comparisons performed in this study. The
simulations assume that the value of the uncertainty is
known and plan according to this known value. Afterwards,
the final dose for the treatment course is computed with the
same uncertainty as in planning. Both arms of the study use
the same random uncertainty assumption. This eliminates the
need for knowledge of the exact value of real patient uncer-
tainty. In actual clinical application of the proposed methods,
in-house measurements of setup uncertainty would be re-
quired.
Standard margin-based plans are optimized using the cri-
teria specified above. In margin-based planning, the target is
the PTV. A pseudovolume termed local normal tissue LNT,
which is a ring extending from 2 cm outside of the CTV to
4 cm outside of the CTV, is used by the optimization process
to attempt to reduce dose outside of the target. After optimi-
zation is completed, dose for the margin-based plan is recal-
culated using fluence convolution, as discussed below, to
generate the dose distribution representative of the patient
subject to random setup uncertainties over the 30-fraction
treatment.
PTP-based plans are optimized using the same criteria as
the margin-based plans with the exception of the target struc-
ture criterion. For PTP, the CTV is used as the target struc-
ture in planning rather than the PTV. A flow chart describing
the PTP optimization process is shown in Fig. 1. During each
iteration of the optimization, an in-house written plugin is
used to convolve each beam’s incident fluence with a
=3 mm Gaussian during the dose computation process.
The dose resultant of the convolved fluence is then used by
the optimizer to determine the next update to the fluence
matrix. Fluence updates are performed on an unconvolved
representation of each beam’s fluence matrix. After optimi-
zation is completed, the dose distribution is representative of
the dose distribution of a patient subject to random uncer-
tainty.
The convolution plugin operates by intercepting the
intensity-modulated fluence before casting the fluence
through the patient geometry. The plugin convolves the flu-
ence with a kernel representing the probability density func-
tion PDF of the random patient positioning uncertainty, as-
sumed to be a Gaussian kernel for this study. This efficiently
simulates the effect of uncertainty over an entire fractionated
treatment course, with an infinite number of fractions. The
convolved fluence is then passed back to the dose calculation
engine. The resultant dose distribution is the result of a con-
TABLE I. Optimization criteria used for generating patient plans, based on
RTOG0126. Values of “Max.” for the volume indicate that the specified dose
should not be exceeded anywhere within the volume.
Structure
Dose
cGy Volume
Target 7920 98%
8470 2%
Rectum 6000 50%
6500 35%
7000 25%
7500 15%
8470 Max.
Bladder 6500 50%
7000 35%
7500 25%
8000 15%
8470 Max.
Left femur 3500 50%
5000 Max.
Right femur 3500 50%
5000 Max.
LNT 5000 Max.
FIG. 1. PTP optimization flow using fluence convolution used in this study.
3882 Moore et al.: Probabilistic treatment planning comparisons 3882
Medical Physics, Vol. 36, No. 9, September 2009
95
volved fluence. Fluence convolution-based dose calculations
are used in the PTP optimization process and in the compara-
tive analysis for margin-based plans.
Fluence convolution is technically only valid for an infi-
nite number of fractions. Unkelbach and Oelfke27 demon-
strated that PTP methods that optimize the expectation value
of the dose can yield undesirable dose undulations when de-
livered in a finite number of fractions. Therefore, they re-
quired a variance reduction term in the objective function to
minimize these undulations.
To determine if our optimization results show such undu-
lations, we perform postoptimization treatment delivery
simulations to simulate multiple 30-fraction treatment
courses for a single patient. This is similar to the stochastic
method used by Craig et al. to validate dose convolution.33 A
single treatment course is simulated by computing the total
dose for 30 fractions, where each fraction is simulated by
shifting the fluence by a random value sampled from a
=3 mm Gaussian and computing the dose. The dose from
each fraction is summed to produce a distribution represen-
tative of the dose accumulated over an entire treatment
course. This process is repeated 100 times to produce a total
of 3000 fractions representing 100 treatment courses. The
results of these treatment courses are then compared to a
treatment course computed using fluence convolution. For
each total treatment dose, the difference in DVH results from
the convolution method is computed. Validation of convolu-
tion is shown on both PTP-based and margin-based opti-
mized fluences.
For evaluation of the clinical acceptability of the auto-
matically generated treatment plans, both PTP-based and
margin-based plans are reviewed by a physician. The physi-
cian determines if each plan is clinically acceptable and
chooses the preferred plan for treatment.
Comparisons between plans are conducted based on the
dose that incorporates the expected random daily setup er-
rors. For each structure, plans are compared based upon the
dose-volume criteria specified during optimization. The vol-
ume receiving the prescription dose and the dose received by
the prescription volume are computed at each point specified
in the plan criteria. Plan criteria that are completely satisfied
by the optimized dose distribution are excluded from the
analysis as the optimizer does not attempt to improve the
plan beyond the defined criteria. For example, given the ob-
jectives used in this study, if the dose to the bladder is below
65 Gy the planning objective would be met; therefore, this
criterion would not be reported. Since the dose distributions
used in this evaluation include the effects of random errors,
both margin-based and PTP methods use the CTV in the
DVH analysis. The PTV is only used in the optimization
process for margin-based planning as it is only a surrogate
for the complete treatment dose on a static plan. In addition
to dose-volume metrics used as optimization objectives, the
mean dose to each structure is computed.
For each of the structures specified in the plan criteria,
TCP and NTCP indices are computed. These are computed
using the Biology tool available under the Plan Evaluation
menu in Pinnacle. Parameters for TCP/NTCP indices are
equal to the defaults for each given organ in the Biology tool.
Table II displays these values. TCP is computed for the target
structure and NTCP is computed for normal tissue structures.
Additionally P+ is computed for each plan. P+ is a compos-
ite measure incorporating all TCP and NTCP indices from
the plan into a single metric which represents the probability
of uncomplicated tumor control. For these metrics, an in-
crease in TCP or P+ is considered beneficial while a de-
crease in NTCP is preferred.
The conformity of the plans is quantified by computing
the dosimetric margin distribution DMD.34 The DMD is a
generalization of the ICRU conformity index2 that measures
the distance a structure can move before crossing a given
isodose line in different directions. DMD evaluations are per-
formed on the fluence-convolved dose distributions for the
CTV to both the 90% prescription line 7100 cGy and the
50% prescription dose line 3960 cGy. The DMD is ob-
tained from 146 equispaced directions around the CTV. The
50% isodose line is evaluated since it corresponds to the
irradiated volume2 and conventionally indicates the location
of the edge of the treated volume.
Clinically, the random component of the setup uncertainty
varies from patient to patient and is unknown at the time of
planning. The sensitivity of the plans generated assuming a
=3 mm random uncertainty to deviations in patient-
specific random uncertainty value T is studied by evaluating
the dose distributions corresponding to halving
T=1.5 mm and doubling T=6 mm the uncertainty
used during the plan optimization. DVH indices are com-
pared and the number of plan objectives met by each is
scored.
TABLE II. Parameters used in TCP and NTCP evaluations. Values are equivalent to the default values given by
the Pinnacle TPS Refs. 40–42.
Type ROI Organ/tumor End point/stage D50 Gamma Alpha/beta Seriality
TCP CTV Prostate Stage B 5270 4.2 10
NTCP Bladder Bladder Contracture 8000 3 3 0.18
NTCP Rectum Rectum Necrosis/stenos 8000 2.2 3 1.5
NTCP Left femur Femur Necrosis 6500 2.7 3 1
NTCP Right femur Femur Necrosis 6500 2.7 3 1
NTCP LNT Normal tissue Necrosis 6500 2.8 3 1
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III. RESULTS
The suitability of using fluence convolution to simulate
the 30-fraction treatment delivery for plan evaluation and
plan optimization is shown in Table III. The variability of
margin-based and PTP-based plans for one hundred 30-
fraction delivery simulations and deviations from convolu-
tion are evaluated using the planning DVH criteria. For
margin-based plans, the convolved dose differs by 0.1%
from the average dose from treatment simulations. The vol-
ume receiving the prescription dose after convolution differs
by 0.02% from the volume receiving the prescription dose
from treatment simulations. The 0.1% variability in dose
observed is much smaller than the 2%–3% accepted variabil-
ity in beam delivery35,36 and is therefore considered clini-
cally acceptable. The maximum and minimum doses devia-
tions are also well within a 2% tolerance. For PTP-based
plans, the difference between the convolution and the aver-
age of the treatment simulations is with 0.1% in dose and
0.3% in volume. The 0.5% variability of the PTP-based plans
for the treatment simulations is larger than the 0.1% ob-
served for the margin-based plans but still well within a 2%
tolerance. The maximum deviation is also larger but within
tolerance. One treatment course simulation varies by 2.1%
from the convolution volume at 7920 cGy. For both methods,
all critical structures aside from the LNT structure remain
below plan criteria for all simulations. The LNT volume in
simulated treatment courses differs by less than 0.1% from
convolution for both methods. While each simulated random
treatment course yields slightly different doses, the variation
is within typical clinical tolerances. In this study, 100% of
simulations produce dose distributions that deliver
7524 cGy 95% of the prescription dose for both PTP-
based and margin-based plans. This exceeds the 90% of pa-
tients expected when using the margin formula of van Herk
et al. and is due to the fact that only random setup uncertain-
ties are considered.
Margin-based planning and PTP planning are successfully
completed on all patient plans. A comparison of isodose pro-
files on a transverse slice through the isocenter for one pa-
tient with PTP-based and margin-based with and without
convolution plans is shown in Fig. 2. As is typical in dose-
volume based optimization, final plans result in a trade-off
between the objective function criteria, with not all treatment
objectives being fully met. All plans meet the specified cri-
teria for left femur and right femur using both methods. One
margin-based planning patient and a different PTP patient
exceed the bladder maximum dose objective. All other blad-
der objectives are met for all patients. One PTP patient ex-
ceeds the 8470 cGy rectum maximum dose objective by
0.3 cGy. Two margin-based plans and two PTP-based plans
exceed the rectum 7500 cGy objective by 36 and 3 cGy for
the margin-based plans and by 5 and 103 cGy for the PTP-
based plans; the 3 and 103 cGy deviations are for the same
patient. All other rectum objectives are met for all patients.
Physician review of the plans indicates that the PTP-based
plan is preferred over the margin-based plan for 21 out of 28
total patients. For one patient, the clinician indicated that
there is no preference between plans. For two of the patients,
TABLE III. Minimum, maximum, range, mean, and standard deviation of DVH criteria observed over the 100 simulated treatment courses for the CTV and
LNT structures compared with convolution. Average difference is the convolution value minus the mean of the simulated treatment courses. RMS value is the
sum of the squared differences of each simulated course from the convolution value. Simulated treatment course values are the difference from convolution
for volumes and the percentage difference relative to convolution for doses.
Convolution
Simulated treatment courses
Min.
%
Max.
%
Range
%
Average
%
RMS
%
Standard deviation
%
Margin based CTV V7920 98.0% 0.7 0.6 1.3 0.0 0.3 0.3
D98 7920 cGy 0.2 0.2 0.5 0.0 0.1 0.1
V8470 0.4% 0.4 0.8 1.2 0.1 0.3 0.3
Max. 8506 cGy 0.0 0.1 0.1 0.0 0.0 0.0
LNT V5000 1.1% 0.1 0.1 0.2 0.0 0.0 0.0
PTP based CTV V7920 97.5% 2.1 1.0 3.0 0.1 0.6 0.6
D98 7890 cGy 1.8 0.7 2.5 0.1 0.5 0.5
V8470 0.0% 1.6 1.5 3.1 0.3 0.6 0.6
Max. 8470 cGy 0.2 0.3 0.5 0.1 0.1 0.1
LNT V5000 0.7% 0.1 0.1 0.1 0.0 0.0 0.0
FIG. 2. Typical isodose profiles on a transverse slice passing through the
isocenter for a the optimized margin-based plan, without inclusion of the
effect of the random patient setup errors, b the optimized margin-based
plan, with inclusion of the random patient setup errors, and c the PTP-
based plan, which inherently incorporates the effect of random patient setup
errors.
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the margin-based plan is preferred due to a slightly greater
amount of the rectum exposed to high doses in the PTP plan.
For four of the patients, the physician rejected both of the
autogenerated plans due to the high dose to the critical struc-
tures. For two additional patients, the physician would reject
only the margin-based plan. None of the PTP-based plans are
rejected without the margin-based plan for the same patient
being rejected. In a true clinical setting, optimization param-
eters for failing plans would have been modified to meet
the planning criteria; however, for consistency, standard cri-
teria are used for all plan evaluations in this study. Histo-
grams of per-patient deviations in the dose-volume indices,
=1001−DVx
PTP /DVx
MP or =1001−VDy
PTP /VDy
MP, where DVx
is the dose received by Vx percentage of the volume for the
structure indicated and VDy is the volume receiving a dose of
Dy for the structure indicated, are shown in Fig. 3. Summary
results of DVH analysis are shown in Table IV. Averaged
over all patients, the CTV D98 is 0.5% lower for PTP as
compared to margin-based planning. The CTV volume re-
ceiving 7920 cGy does not differ significantly for this objec-
tive p=0.092. All p values are obtained from a two-tailed
paired t test. The maximum 8470 cGy dose objective shows
no significant differences between PTP- and margin-based
planning p=0.44. PTP shows a 48% decrease in volume
receiving the 5000 cGy maximum dose objective for LNT
with p0.0001. There is a 1.9% decrease in the maximum
dose delivered to the target with p=0.0095.
Histograms of per-patient deviations in the mean dose,
=1001−D¯ PTP /D¯ MP, where D¯ is the mean dose delivered
to the structure indicated, are shown in Fig. 4. Sum-
mary results of mean dose analysis are shown in Table V.
The CTV on average receives a slightly higher mean dose
+0.74% , p0.0001. PTP results in a significantly
p0.0001 lower mean dose to critical structures. Mean
doses to all critical structures on all patient plans are reduced
compared with margin-based plans as follows: Bladder,
14.2%; rectum, 8%; left femur, 11.3%; right femur,
11%; and LNT, 12.9%.
Histograms of absolute per-patient deviations in the P+,
TCP, and NTCP, =BPTP−BMP, where B is the P+, TCP, or
FIG. 3. a The percentage difference in the CTV doses to 98% of the vol-
ume between the margin-based and PTP-based plans for each patient. The
average difference of 0.5% is indicated by the small bar. Negative values
indicate a lower dose for the PTP-based plans. 0.5% corresponds to a 39.6
cGy difference. b The percentage difference in the LNT volumes receiving
5000 cGy. The average difference of 48% is indicated by the small bar.
Negative values indicate a lower volume for the PTP-based plans. 48%
corresponds to a 409 cc reduction in volume. c The percentage difference
in the local normal tissue maximum doses between the margin-based and
PTP-based plans for each patient. The average difference of 1.9% is indi-
cated by the small bar. 1.9% corresponds to a 120.7 cGy difference.
TABLE IV. Mean, maximum, minimum, and p value for the difference in doses and difference in volumes between margin-based and PTP-based plans for the
listed objectives. Plan objectives not listed were met by both methods for all plans.  is used to indicate “difference in.”
Structure
Dose
cGy
Volume
%
dose
%
Max.
%
Min.
% p
volume
%
Max.
%
Min.
% P
Target 7920 98 0.5 0.6 2.4 0.0013 0.4 4.7 3.0 0.0916
8470 2 0.1 1.4 0.7 0.1040 66.6 780.1 86.6 0.4415
Rectum 7500 15 a
8470 b
Bladder 8470 c
LNT 5000 1.9 4.9 10.0 0.0095 47.9 50.2 94.4 0.0001
aAll plans met objectives except for two PTP-based plans and two margin-based plans.
bAll plans met criteria except for one PTP-based plan.
cAll plans met criteria except for one PTP-based plan and one margin-based plan.
FIG. 4. a The percentage difference in CTV mean dose between the
margin-based and PTP-based plans for each patient. The average difference
of 0.7% is indicated by the small bar. Negative values indicate a lower dose
for the PTP plans. 0.7% corresponds toh a 60.1 cGy difference. b The
percentage difference in LNT mean dose between the margin-based and
PTP-based plans for each patient. The average difference of 12.9% is indi-
cated by the small bar. 12.9% corresponds to a 268 cGy difference.
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NTCP value for the structure indicated, are shown in Fig. 5.
Summary results of P+, TCP, and NTCP analysis are shown
in Table VI. The PTP-based plans on average show an abso-
lute increase in P+ of +2.5% over margin-based plans.
p=0.0002. The TCP for both PTP-based and margin-based
plans are equal at 99.9% for all but one plan. That plan
shows an increase in TCP of 0.01% from 88.1% to 89.2% for
the PTP-based plan. The rectum NTCP decreases for PTP-
based plans by an average of 1.9% with p=0.0014. Rectal
NTCP differences range from an increase of 2.8% to a de-
crease of 7% for PTP. Bladder NTCP values decrease on
average by 0.7%, p0.0001. LNT NTCP is decreased by
0.06%, p=0.0028. The left and right femurs for all patients
for both PTP-based and margin-based plans have 0 NTCP.
For all patients, PTP gives 0 NTCP for LNT. Five margin-
based plans have an NTCP of 0.01 for LNT; all other plans
have 0 NTCP for LNT.
A histogram of the 7100 cGy DMDs for the margin-based
and PTP-based plans for a sample patient is shown in Fig. 6.
Table VII shows the summary of the DMD values. For each
patient, the average dosimetric margin for the PTP-based
plans is less than that for the margin-based plans. The aver-
age dosimetric margin over all patients at 7100 cGy shows a
significant p0.0001 difference between margin-based
0.90 cm and PTP-based 0.65 mm plans. For 25 out of 28
patients, the dosimetric margin at 7100 cGy for PTP-based
plans is smaller than that of the margin-based plans in all
of the 146 evaluated directions. The average dosimetric mar-
gin over all patients at 3960 cGy shows a significant
p0.0001 difference between margin-based 1.90 cm and
PTP-based 1.60 cm plans. For 27 of the patients, the dosi-
metric margin at 3960 cGy for PTP-based plans is smaller
than that of margin-based plans in all of the 146 evaluated
directions. PTP produces plans that are more conformal re-
sulting in smaller dosimetric margins and a reduction in
doses outside of the target. For PTP-based plans a slight
increase 1.6% in monitor units is observed compared to
margin-based plans; this indicates little increase in the com-
plexity of PTP-based plans.
The sensitivity of the structure dose coverage to the setup
uncertainty estimate used in optimization is tested for both
margin-based and PTP-based plans. Table VIII displays the
difference in mean dose when the patient-specific random
setup uncertainty T is double and half the value that is used
for the optimization. If the patient setup uncertainty is de-
creased with respect to the estimated uncertainty used during
planning T, mean dose for both PTP-based and
margin-based plans increases for all structures except the
LNT structure which reports a lower mean dose from both
methods. With increased setup uncertainty during treatment,
the converse holds true. These results are consistent with a
decrease/increase in the dose blurring as the setup uncer-
tainty is reduced/increased. Table IX compares the plans us-
ing the optimization DVH indices for unmet criteria. Again,
consistent with dose blurring, as treatment uncertainty in-
creases, the dose to the target decreases and deviation be-
tween target simulation dose increases. Dose to critical struc-
tures decreases as well as the deviation between OAR
FIG. 5. a The absolute difference in P+ between the margin-based and
PTP-based plans for each patient. The average difference of 2.45% is indi-
cated by the small bar. Positive values indicate a better treatment outcome
for the PTP-based plans. b The absolute difference in rectum NTCPs be-
tween the margin-based and PTP-based plans for each patient. The average
difference of 1.9% is indicated by the small bar. Negative values indicate a
lower complication rate for the PTP-based plans. c The absolute difference
in bladder NTCPs between the margin-based and PTP-based plans for each
patient. The average difference of 0.7% is indicated by the small bar. d The
absolute difference in LNT NTCPs between the margin-based and PTP-
based plans for each patient. The average difference of 0.06% is indicated
by the small bar.
TABLE V. Mean, maximum, and minimum differences in mean doses be-
tween margin-based and PTP-based plans, with associated p values for ob-
jective structures.  is used to indicate “difference in.”
Structure
mean
%
Max.
%
Min.
% p
CTV 0.7 2.0 1.2 0.0001
Rectum 8.0 1.6 15.5 0.0001
Bladder 14.2 4.5 26.4 0.0001
Left Femur 11.3 5.0 20.6 0.0001
Right Femur 11.1 3.0 18.5 0.0001
LNT 12.9 9.9 18.2 0.0001
FIG. 6. Dosimetric margin distributions for sample a margin-based plan
and b PTP-based plan. The average dosimetric margin for margin-based
plans is 9.8 mm as indicated by the bar on a. The average dosimetric
margin for PTP plans is 7.2 mm as indicated by the bar on b.
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simulation dose as uncertainty increases. For T=6 mm, all
PTP- and margin-based plans failed to meet the CTV
D987920 cGy dose criteria; however, eight PTP and six
margin-based plans that initially failed to meet the CTV
Dmax8470 cGy then met the criteria, consistent with dose
blurring. With T=6 mm, no critical structure doses ex-
ceeded planning criteria. For T=1.5 mm, 23 PTP plans and
10 margin-based plans that initially did not fully meet the
CTV D987920 cGy criteria then met the criteria. How-
ever, two additional PTP and four additional margin-based
plans failed to meet the Dmax8470 cGy criteria. Further-
more, four additional OAR criteria were not met with
T=1.5 mm for both the PTP- and margin-based plans. Ad-
equate coverage is achieved if the uncertainty during treat-
ment is less than or equal to the uncertainty used during the
planning process for either margin-based planning or PTP.
When the uncertainty during treatment is greater than the
uncertainty used during the planning process, both methods
have reduced coverage. These results demonstrate that if un-
certainty is underestimated, PTP methods will produce ac-
ceptable coverage. In the case of uncertainty being overesti-
mated, neither PTP- nor margin-based planning will produce
the required coverage. In both PTP- and margin-based plan-
ning, if there is low confidence in the uncertainty estimate, it
is best to overestimate the uncertainty to ensure coverage.
IV. DISCUSSION
In this study, a simple method for incorporating random
patient setup uncertainty into plan optimization is imple-
mented. This method does not require changing the objective
functions used in optimization. The results show that PTP-
based plans produce similar target coverage to margin-based
plans while reducing dose to critical structures and LNT and
produce more conformal plans without increasing complex-
ity. This simple method of incorporating random errors into
treatment optimization is significant since it is a straightfor-
ward method to improve the therapeutic ratio that can be
implemented into an arbitrary optimization system.
PTP allows for uncertainties to be handled directly by the
optimizer. This allows an optimal solution to be generated
that does not require the addition of margins. PTP optimized
plans result in a tighter dosimetric margin around the target.
Margin-based plans using a fixed expansion tend to generate
effective dosimetric margins that are larger than the planning
margin.34 This larger margin results in more normal tissue
receiving therapeutic doses.
Our findings that PTP reduces normal tissue doses and
NTCP are similar to the findings of previous studies. For
focal liver tumors, Balter et al. reported that convolving the
dose with a population-based random Gaussian can reduce
the effective treatment volume by 6%–8% as compared to a
margin-based approach.37 Yang et al. reported that incorpo-
rating uncertainty around targets and OARs by way of a
score function composed of scores on multiple shifted plan-
ning scans weighted by their probability resulted in greater
OAR sparing when compared to margin-based approaches,
including methods that incorporate a PRV margin.31
As is demonstrated in Fig. 2, incorporating the effects of
random setup errors into the dose evaluation results in a blur-
ring of the patient dose distribution. This finding is in agree-
ment with numerous previous authors.6,38 Although it is
trivial to incorporate such a blurring into the dose calculation
and display process and require very little additional compu-
tational overhead, clinically, no treatment planning systems
TABLE VI. Mean, maximum, and minimum differences in P+, TCP, and NTCP between margin-based and
PTP-based plans with associated p values for objective structures.  is used to indicate “difference in.”
Structure Type
mean
%
Max.
%
Min.
% P
All P+ 2.45 7.60 2.10 0.0002
CTV TCP 0.01 0.30 0.00 0.3262
Rectum NTCP 1.88 2.80 7.00 0.0014
Bladder NTCP 0.67 0.00 2.60 0.0001
Left femur NTCP 0.00 0.00 0.00 –
Right femur NTCP 0.00 0.00 0.00 –
LNT NTCP 0.06 0.00 0.40 0.0028
TABLE VII. Mean, maximum, and minimum dosimetric margins for 7100 and 3960 cGy for both margin-based
and PTP-based plans with p values of the difference between margin-based and PTP-based plans.
Dose
7100 cGy 3960 cGy
Mean
cm
Max.
cm
Min.
cm
Mean.
cm
Max.
cm
Min.
cm
Margin 0.90 1.63 0.37 1.90 4.11 0.92
PTP 0.65 1.47 0.17 1.60 3.67 0.62
P 0.0001 0.0001
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do this. Currently, plans are presented to the physician show-
ing isodose profiles and DVHs as if the patient is in an iden-
tical treatment position with respect to the beams during each
treatment delivery. By viewing a static dose distribution, the
gradients in the dose distributions evaluated by the clinicians
are sharper than what is actually achieved during multifrac-
tional treatment delivery. A method more representative of
the actual patient dose is to include the best estimate of the
random component of the random patient setup uncertainty
into the dose calculation, either using the fluence
convolution39 or dose convolution38 approaches prior to dis-
playing isodose and DVHs. For margin-based planning, such
analysis would require evaluating DVHs for structures with
margins added that only account for systematic setup errors
or evaluation of the coverage probability. It is possible,
though not quantifiable at this point, that displaying a more
clinically realistic dose distribution to the clinician could al-
ter treatment planning decisions.
For the purposes of this study, other than the sensitivity
study, exact knowledge of the random uncertainty distribu-
tion was assumed. Exact knowledge of the random uncer-
tainty distribution can only be had after an entire treatment
course has been completed. Random uncertainty estimates
are commonly obtained from a large population of similar
patients. Additionally from a large population of patients, the
uncertainty in the random setup uncertainty estimate can be
obtained. With knowledge of the uncertainty in the random
uncertainty estimate, a planning setup uncertainty can be
chosen based upon a percentage of the uncertainty distribu-
tion. It may be the case that the best value used in planning
is the Nth percentile of the distribution of uncertainty esti-
mates, where N is the percentage of patients. For this case,
90% would correspond with the margin formulations of van
Herk et al.4–6
In this study, we assume that systematic setup uncertain-
ties are negligible. While clinically unrealistic, use of adap-
tive therapy setup protocols,13,14 where the patient position is
imaged for the first several approximately five fractions,
then repositioned based on the systematic error derived from
those measurements, has been shown to significantly reduce
systematic setup errors. Even if systematic errors persist, the
methods used in this study are still relevant. When system-
atic errors remain, a margin can be added around the struc-
tures to account for systematic uncertainty alone while al-
lowing PTP to account for random uncertainty.
While this study only accounted for random rigid patient
setup variations, other random uncertainties such as in-
trafraction motion that can be modeled using a PDF could be
incorporated using similar methods. Evaluation of these un-
certainties is left to future studies.
V. CONCLUSIONS
A PTP method that directly incorporates random uncer-
tainty into the standard IMRT optimization of a commercial
TPS has been implemented and tested. PTP results generated
using this implementation are compared with margin-based
plans. PTP-based plans show similar coverage to the margin-
based plans. A small reduction in the dose to the target plan-
ning objectives is observed but dose to the local normal tis-
sue structure is significantly reduced. OARs and LNT show
TABLE VIII. Differences in the structure mean dose values when the patient
plan is subject to half T=1.5 mm and double T=6 mm the estimated
=3 mm random uncertainty used during the optimization for margin-
based and PTP-based plans.
Half
%
Double
%
Margin Bladder 0.3 1.0
CTV 0.2 1.6
LNT 0.4 1.8
Left femur 0.3 1.1
Right femur 0.4 1.3
Rectum 0.3 1.0
PTP Bladder 0.1 0.2
CTV 0.4 2.6
LNT 0.3 1.6
Left femur 0.3 1.2
Right femur 0.4 1.3
Rectum 0.3 1.0
TABLE IX. Mean dose and standard deviation over 28 patients for the listed criteria for plans optimized with
=3 mm but recomputed with T=1.5, 3, and 6 mm. As uncertainty increases, the dose at target objectives
decreases and vice-versa. As uncertainty increases, the dose at OAR objectives decreases and vice-versa.
Objectives not listed were met by all plans.
Dose
1.5 mm 3 mm 6 mm
PTP Margin PTP Margin PTP Margin
CTV 98% cGy 8005 7974 7878 7930 7198 7494
Standard deviation cGy 48 30 69 38 153 133
Rectum 25% cGy 5441 5797 5382 5743 5193 5554
Standard deviation cGy 864 796 852 783 805 743
Rectum 15% cGy 6507 6811 6434 6734 6189 6486
Standard deviation cGy 744 672 727 650 669 600
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decreased mean dose using PTP methods as compared to
margin-based methods while target mean dose slightly in-
creases. Biological indices indicate that PTP has a similar
TCP with reduced NTCP resulting in a higher P+. Effective
dosimetric margins are smaller in PTP-based plans as com-
pared to margin-based plans indicating more conformal
plans. PTP produces plans that maintain similar target cov-
erage while reducing dose to all other structures.
The use of fluence convolution to simulate the dose blur-
ring effect of the 30-fraction treatment courses is valid. Com-
pared with average from delivery simulations, fluence
convolution-based target doses and volumes differed by
0.1%. Use of convolution instead of simulation during op-
timization is within clinical tolerance.
The sensitivity of PTP-based plans to deviations in the
patient-specific uncertainty with respect to that used in plan-
ning is comparable to the sensitivity of margin-based plans.
For both margin-based and PTP methods, if the setup uncer-
tainty is less than what was used for planning, dose increases
to the target and to nearby critical structures due to sharpen-
ing of the dose distribution. If the setup uncertainty is larger
than what is used for planning, dose decreases to the target
and to nearby critical structures due to blurring of the dose
distribution
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Abstract	
Purpose:  To develop a probabilistic treatment planning (PTP) method which is robust to 
systematic patient setup errors and to compare PTP plans with plans generated using a 20 
Planning Target Volume (PTV) margin optimized to give the same target coverage probability as 
the PTP plan.  
Methods:  Plans adhering to the RT0G‐0126 protocol are developed for 28 prostate patients 
using PTP and margin‐based planning.  For PTP, an objective function that simultaneously 
considers multiple possible patient positions is developed.  PTP plans are optimized using 25 
Clinical Target Volume (CTV) structures and Organ at Risk (OAR) structures.  The desired CTV 
coverage probability is 95%. Plans that cannot achieve a 95% CTV coverage probability are re‐
optimized with a desired CTV coverage probability reduced by 5% until the desired CTV 
coverage probability is achieved. Margin‐based plans are created which achieve the same CTV 
coverage probability as the PTP plans by iterative adjustment of the CTV‐to‐PTV margin.  Post 30 
optimization, probabilistic dose volume coverage metrics are used to compare the plans. 
Results:   For equivalent target coverage probability, PTP plans significantly reduce coverage 
probability for rectum objectives (‐17% for D35<65Gy, p=0.0010; ‐23% for D25<70Gy, p<0.0001; 
and ‐27% for D15<75Gy, p<0.0001).  Physician assessment indicates PTP plans are entirely 
preferred 71% of the time while margin‐based plans are entirely preferred 7% of the time. 35 
Conclusions:  For plans having the same target coverage probability, PTP has potential to 
reduce rectal doses while maintaining CTV coverage probability. In blind comparisons, 
physicians prefer PTP plans over optimized margin plans. (Work supported by NIH 
P01CA116602 and T32CA113277) 
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Introduction	40 
In planning fractionated external beam radiation therapy, treatment plans developed should be 
robust to random and systematic inter‐fractional patient setup errors to ensure the target 
volume receives a tumoricidal dose and that organ at risk doses are kept below complication 
thresholds.  The common approach to accommodate setup errors is use a planning target 
volume (PTV) as a surrogate for the clinical target volume (CTV) during the planning process.1, 2  45 
The intent of the PTV is to ensure that the CTV receives the prescription dose for an expected 
percentage of the setup errors.  Geometrically, this is accomplished by expanding the CTV by a 
margin to create the PTV.  Margin recipes have been developed which suggest the margin size 
as functions of the standard deviations (SDs) of random and systematic errors. 3‐6  In principle, 
site and institution‐specific SDs can be obtained by direct measurements of a suitable 50 
population of patients and margins directly computed.  In practice, margins are based on 
clinical experience and are applied as uniform expansions of the CTV in 3‐dimensions, with 
possible adjustment depending on the site, and adjacent critical structures.  In either case, due 
to the fact that the dose distribution imperfectly conforms to the PTV volume, the percentage 
of setup errors in which the CTV receives the prescribed dose level can differ from what is 55 
expected for a given PTV margin. 7, 8  The CTV coverage is dictated by the treated volume, which 
is only indirectly a function of the PTV. 
  An alternative to margins is to use probabilistic treatment planning (PTP) or robust 
optimization methods, which ensure CTV coverage by optimizing the treatment plan dose 
distribution while incorporating the effects of the patient setup uncertainty.9‐22  PTP methods 60 
do not require specification of PTVs or planning risk volumes (PRVs).  Instead, given the 
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probability distributions of setup errors, the plan optimization constructs a treated volume to 
meet the planning criteria without constricting the dose to predefined PTVs/PRVs.  When the 
locational probability distributions of a CTV and organs at risk (OAR) volumes overlap, PTP 
optimization can directly optimize the trade‐offs.  PTP permits creation of non‐uniform static 65 
dose distributions to meet the planning goals when the cumulative effect of patient setup 
errors are folded into the dose evaluation.   
Potential benefits of PTP have been documented for methods designed to 
accommodate just the random component of the positioning uncertainty16, 17, 20, and the 
combined effects of random and systematic positioning uncertainties9, 13‐15, 18, 21, 22. Considering 70 
only the random component, using a dose convolution approach, Balter et al.17 found that PTP 
reduces the treated volume by 6‐8% as compared to a margin based approach for focal liver 
tumors.  Using multiple offset replicas of a the patient’s geometry to accommodate random 
errors, McShan et al.20 confirmed that PTP reduced normal tissue doses and created plans 
which were more robust to positioning errors than margin‐based plans.  For prostate, Moore et 75 
al.16 used a fluence convolution to mimic the random patient positioning variability in the 
accelerator coordinate system and found that PTP reduced the dose to local normal tissue by 
48% and increased the probability of uncomplicated tumor control (P+) by 2.5% compared to 
margin‐based methods.   
  Considering both random and systematic errors, using a stochastic optimization of P+ 80 
including the effects of setup uncertainties, Lof et al.9 demonstrated the potential for PTP to 
increase P+ compared to margin‐based methods.  For various treatment sites and using 
different Effective Uniform Dose (EUD)‐based PTP optimization approaches,  Baum et al.22 , 
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Birkner et al. 18, Yang et al. 21, and Witte et al.13 each found increased OAR sparing compared to 
a margin‐based methods.  Yang confirmed improved OAR sparing even over methods that 85 
incorporate an ICRU 62 PRV.21  Gordon et al.14 15 used probabilistic DVH‐based coverage 
criteria, evaluated via sampling setup error probability distribution functions, as an optimization 
goal, and found that, compared with standard margins, a ~20% average reduction in volume 
receiving the treatment dose could be achieved while maintaining desired target coverage 
probabilities,  or an increased target coverage probability could be achieved for same OAR 90 
dose.14   While the potential benefits of PTP using EUD or specialized coverage‐based objective 
functions seem clear, except for Gordon et al14, 15 who used 27/28 prostate patients and Witte 
et al. who used 19 prostate patients, these prior PTP studies are mainly demonstration studies, 
limited to at most 3 patients per treatment site.  Furthermore, none of these studies is backed 
up with physician evaluation of the resultant treatment plans.   95 
The purpose of this work is to explicitly incorporate dosimetric effects of random and 
systematic setup uncertainties into treatment plan optimization by performing a joint 
optimization over multiple probable patient setup positions.  Due to its ability to consider 
relative locations of targets and risk structures during the optimization, it is hypothesized that 
this optimization method will produce plans with similar target coverage while reducing the 100 
dose received by treatment risk structures compared with margin‐based plans.  This is 
evaluated by comparing the PTP plans with margin‐based plans.  The primary differences from 
previous work include study of a large patient population, use of dose‐volume objectives for 
optimization, and analysis with coverage probability, probabilistic dose‐volume histograms, and 
physician assessment. 105 
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Methods	and	Materials	
This study compares margin‐based and PTP‐based treatment plans for a series of 28 prostate 
patients. For each patient, the process is split into three steps: (1) a PTP plan is created and the 
coverage probability is evaluated; (2) a margin‐based plan is created with the same coverage 
probability (within tolerance) as the PTP plan; (3) metrics are compiled for each plan and used 110 
for plan comparison. This process is repeated until the entire patient population has been 
analyzed. Figure 1 shows the overall flow of the comparison process. The patient contouring 
and planning steps are described in detail in the sub‐sections below. 
Planning	parameters	
Imaging and contour data from 28 prostate patients treated under an approved institutional 115 
review board protocol are used in this study.  The plan used for the patient treatment is 
discarded and new plans are generated for this virtual plan comparison study.  Patient plans are 
generated with a research version of Pinnacle3 8.1y (Philips Medical Systems, Fitchburg, WI) 
using a 7‐beam setup with beam angles of 30o, 80 o, 130 o, 180 o, 230 o, 280 o and 330 o, with the 
180o beam corresponding with a posterior beam.  The dose matrix resolution of 4×4×4 mm3 is 120 
used during the intensity modulation optimization.  The CTV is defined as the prostate plus 
seminal vesicles.  PTP directly uses the CTV during the optimization.  For margin‐based 
planning, the PTV is a uniform expansion of the CTV.  The size of the CTV‐to‐PTV margin is 
adjusted to match the CTV coverage achieved during the PTP planning (described below).  The 
optimization objectives are based on the RTOG‐0126 protocol (shown in Table 1).  The PTP 125 
plans use custom objective functions (described below) while the margin‐based plans use the 
111 
 
standard objective functions available in Pinnacle.  The patient setup errors are assumed to be 
normally distributed with a standard deviation in systematic uncertainty of 3 mm in each 
direction and the standard deviation in the random setup error of 3 mm.  The use of normally 
distributed setup errors equal in each direction for this planning comparison study is justified in 130 
the discussion.  
Probabilistic	treatment	planning	
The main PTP optimization (Figure 2) consists of two stages; creating an initial PTP plan 
followed by adjusting objective function weights to achieve acceptable coverage.  To improve 
efficiency, the PTP optimization (Figure 4) is wrapped in a loop (Figure 3) which progressively 135 
increases the number of systematic errors sampled during the optimization.  At the core of the 
PTP optimization is computation of the objective function and gradients used for updating the 
beam intensity profiles during the optimization.  At initiation, objectives and weights are 
defined as shown in Table 1.  An additional zero‐weight target objective is added using a 
contour created by expanding the CTV contour by 1 cm. This objective ensures that active 140 
intensity values exist in locations where the target can be shifted to during the optimization.  
Since this objective has zero weight, it has no effect on the solution other than setting the initial 
intensities.   
The general flow of creating an initial PTP plan is shown in Figure 3.  At initiation, the optimizer 
defines an initial uniform beam intensity which fully covers structures identified as target 145 
objectives for each beam.  Systematic setup errors are simulated by shifting the dose 
distribution with respect to the patient anatomy and evaluating the objective function multiple 
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times during the optimization.  Initially, the number of systematic offsets ݊ܵݕݏ ൌ 8. 
Optimization proceeds till convergence, then ݊ܵݕݏ  is doubled and the inner optimization 
process restarts using the last intensity matrix as the initial intensity matrix.  When ݊ܵݕݏ ൌ 128 150 
the initial PTP optimization is complete.  
The inner loop of the PTP process is shown in Figure 4.  Note that initiating the process 
with  the  intensity matrix optimized  in prior  iterations,  the process  is  jump‐started permitting 
convergence  with  fewer  iterations.    Random  setup  uncertainties  are  incorporated  into  the 
optimization process in the dose computation step by convolving each beam’s incident fluence 155 
with a σ=3 mm Gaussian  in the dose calculation process.   See  (Moore et al. 2009)  for details.  
Following  dose  computation,  the  planning  objective  function  is  evaluated  for  a  sequence  of 
݊ܵݕݏ randomly  sampled  patient  systematic  errors.    Assuming  the  dose  distribution  in  the 
accelerator  coordinate  system  is  invariant  to  small  patient  shifts23,  a  systematic  setup  error 
corresponds with  an  offset  of  the  dose  distribution with  respect  to  the  patient’s  anatomy.  160 
Offsets ݏ are  sampled  from  a Gaussian  distribution with  Σ=3 mm.    Each  sampled  systematic 
setup  error ݏ and  associated  objective  function ܨݏ  (described  below)  evaluation  therefore 
corresponds  with  a  probable  treatment  course.    Every ݏ generates  an  objective  function 
gradient matrix, ܩ݅,ݏ, where the 3D matrix contains elements for each voxel ݅ of the dose matrix.  
The  cumulative  objective  function  gradient  for  each  voxel ܩ݅ is  used  to  update  the  beam 165 
intensity matrix during the optimization, and the total objective function ܨ is used to evaluate 
optimization convergence.  The optimization terminates when the objective function ܨ changes 
by  less than 1×10‐6  from the value  in a preceding  iteration or when 500  iterations have been 
completed.   
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Objective	function	170 
Dose‐volume based objective functions are used in the simultaneous optimization over multiple 
sampled systematic errors.  A standard maximum dose‐volume objective function can be 
expressed as  
݂ெ௔௫஽௏ு ൌ 1
௥ܰ௢௜
ቌ݌෍ܪ൫ܦ௏ೃೣ െ ܦ௜൯ ∙ ܪሺܦ௜ െ ܦோ௫ሻ ∙ ሺܦ௜ െ ܦோ௫ሻଶ
ேೝ೚೔
௜
ቍ 
where  ௥ܰ௢௜ is the number of voxels in the region of interest (ROI) in which the dose‐volume 
objective is being applied, ݌ is the relative weight of the objective and is used when multiple 175 
objective functions are summed, ܦோ௫ is the desired prescription dose, ܦ௏ೃೣis the dose at the 
prescription volume such that ܸ൫ܦ௏ೃೣ൯ ൌ ோܸ௫, ܦ௜  is the dose in voxel ݅ and H is the Heaviside 
function.  A minimum dose‐volume objective, ݂ெ௜௡஽௏ு, can be similarly defined.  Details of 
dose‐volume‐based objective functions are described by Wu and Mohan24. 
In PTP optimization the dose‐volume objective function is evaluated for multiple 180 
potential treatment courses. Each treatment course is represented by a systematic shift ݏ of the 
patient anatomy. For a given shift, ݏ, the objective function is calculated by replacing ܦ௜  with 
the value from the shifted anatomy ܦ௜ା௦ and calculating ܦ௏ೃೣ  for the shifted dose distribution 
ܦ௏ೃೣ,௦ giving 
௦݂ெ௔௫஽௏ு ൌ 1௥ܰ௢௜ ቌ݌෍ܪ൫ܦ௏ೃೣ,௦ െ ܦ௜ା௦൯ ∙ ܪሺܦ௜ା௦ െ ܦோ௫ሻ ∙ ሺܦ௜ା௦ െ ܦோ௫ሻ
ଶ
ேೝ೚೔
௜
ቍ 
The total objective function for a single ROI is obtained by summing over each systematic error 185 
sampled: 
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݂ ൌ ෍ ௦݂ெ௔௫஽௏ு
௡ௌ௬௦
௦
 
This results in each shifted anatomy contributing a component of the total objective function 
effectively creating a simultaneous optimization over all sampled shifts. 
  Note that in the equations above, a Heaviside function dependent on ܦ௏ೃೣ,೚,௦ is used 
such as ܪ൫ܦ௏ೃೣ,೚,௦ െ ܦ௜ା௦൯.  ܦ௏ೃೣ,೚,௦ is dependent on the dose distribution underlying a specific 190 
shift and must be recomputed for each shift. Generally, ܦ௏ೃೣ,೚,௦ will vary from shift to shift and 
thus changes the range of voxels the objective function operates on.  
Weight‐adjusted	PTP	plan	
Post initial optimization, the PTP plan is adjusted to ensure that the CTV D98 dose volume metric 
achieves  a  desired  coverage  probability14,  15	ܳ஽ ,  where  the ܳܦ  gives  the  probability  of  a 195 
treatment course meeting the specified dose volume metric.  To obtain a plan with the desired 
ܳܦ, the planning objective weights are adjusted using an  iterative binary search. Only rectum 
and bladder weights are changed, and adjusted bladder weights are equal to adjusted rectum 
weights.    Initially,  the  desired  coverage  probability  (ܳܦ)  is  set  to  95%.    The  iterative  binary 
search  investigates the weight range between 0 and 100, and halves the search range at each 200 
step until the desired weight is located.  If the desired ܳܦ cannot be achieved, ܳܦ is reduced by 
5%  and  the  search  process  re‐initiated  until  an  achievable  value  is  reached.    The  iterative 
weight  search process  is  stopped when  the  achieved  coverage  is within 0.5% of  the desired 
coverage or the change in weight would be less than 1. The end result of this process is the final 
optimized PTP plan with a known ܳܦ. 205 
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Coverage	optimized	margin	plan	
To provide a fair comparison between margin‐based planning and PTP, a margin‐based 
plan  is  created which  as  the  same ܳܦ as  the  final  PTP  plan.    The method  used  to  create  a 
margin‐based plan with a specific ܳܦ is similar to the iterative procedure described by Gordon 
et  al.15  The  objective  function weights  for  the margin‐based  plan  are  given  in  Table  1.    A 210 
uniform  CTV‐to‐PTV margin ܯܶ is  used.    To  enforce  OAR  avoidance,  each  OAR  structure  is 
expanded by 1 cm  to produce  a PRV.   Note,  this 1 cm margin  roughly  corresponds with  the 
value which would be  recommended using  the van Herk and Stroom margin  formulas.4‐6 The 
PRVs  are  not  changed  during  the  margin  optimization  process,  but  the  CTV  margin ܯܶ is 
permitted  to vary  in  the  range of 0 cm  to 1.0 cm.   Similar  to  the process used  to determine 215 
appropriate weights  for  the PTP plan,  a binary  search  algorithm  is used  to  cut  the  range of 
margin  values  in  half  at  each  step  until  the  desired  coverage  probability  is  reached.  The 
iterative process is stopped when the achieved coverage is within 0.5% of the desired coverage, 
or the change in margin would be less than 0.05 cm. 
Comparison	Metrics	220 
For both the final optimized PTP plan and the coverage optimized margin plan, coverage 
probabilities for all planning structures are computed along with Probabilistic Dose Volume 
Histograms (PDVHs) and Dose Volume Coverage Maps (DVCMs)15 using the methods developed 
by Gordon et al7, 14.  A DVCM is a probability map which gives the probability of dose‐volume 
values for a simulated set of setup errors.  A DVCM is constructed by generating DVHs for many 225 
systematic shifts and computing the probability that the DVH curve lies above each dose‐
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volume point. For this study, DVCMs are created assuming normally distributed 3 mm 
systematic and 3 mm random setup errors.  Coverage values are read off at DVCM dose‐volume 
pairs.  To compare PTP and margin‐based plans, coverage values are output for each 
optimization criteria dose volume pair.   A PDVH is a pseudo DVH created by interconnecting 230 
points at a given probability level on a DVCM.  To assist in plan comparison, DVCMs are 
imported into Matlab for display.  Planning criteria for each structure are overlaid on the 
DVCMs to ease data interpretation.  For a given patient, coverage values for two different 
planning scenarios can be compared by looking at the difference in the DVCMs.   Dose‐Volume 
Coverage Difference Maps are computed by subtracting one DVCM from another, e.g. the 235 
DVCM from the margin‐based plan is subtracted from the DVCM from the PTP plan.  DVCDM 
map values range from ‐1 to 1.  Negative values indicate that the PTP plan has lower coverage 
for the dose‐volume pair and positive values indicate that the PTP‐base plan has a higher 
coverage for the dose volume pair.  To avoid dose interpolation errors, dose is recomputed on a 
2×2×2 mm3 grid prior to coverage probability evaluations. 240 
For comparing CTV PDVHs, 95 percentile values are used, which means that DVH values 
for 95% of the errors simulated will lie above the PDVH curve.  For OARs, 5 percentile values are 
used so that 5% of the with‐error simulated DVH values lie below the PDVH curve.   
For each patient, DVHs and PDVHs for PTP and margin‐based plans are also evaluated by 
two physicians to determine plan acceptability and preference.  DVH and PDVH curves are 245 
generated and displayed for the target, bladder, rectum, left femur and right femur structures. 
PDVHs are computed as above. For targets, DVHs were presented for nominal PTVs obtained by 
expanding the CTVs uniformly by 0.7cm, except posteriorly where the expansion is 0.3cm. 
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These nominal PTVs were used in preference to the actual PTVs used in optimizing margin‐
based plans, since they corresponded to current clinical practice at our institution, and 250 
therefore produced target DVHs that the physician could compare to familiar clinical examples.  
All curves for a given analysis type are presented on a single plot for each patient.  Markers are 
placed on the graph to indicate the planning objectives used during optimization. To avoid bias, 
PTP and margin‐based plans for each patient are randomized and labeled as A or B.  Plots are 
presented to the physician to determine if a plan would be acceptable to treat and if both plans 255 
are acceptable, which plan would be the preferred plan to treat the patient.  
Results	
An example of a static DVH and a PDVH is shown in Figure 5. Table 2 lists the physician 
preference for each plan. Using static DVH plots for comparison, both physicians prefer the PTP 
plan for 23 patients while the margin plan is preferred for 2 patients. For 3 patients, one 260 
physician prefers the PTP plan, while the other prefers the margin plan. Using PDVH plots for 
comparison, both physicians prefer the PTP plan for 21 patients while the margin plan is 
preferred for 4 patients. For 3 patients, one physician prefers the PTP plan while the other 
prefers the margin plan. For 20 of the 28 patients, all physicians prefer the PTP plans using all 
assessment methods. The margin plan is preferred using all methods for only 2 patients. 265 
For all patients, the margin required to meet the coverage in the PTP plan was recorded. The 
average margin required to match the PTP plan was 0.60 cm (min 0.46 cm, max 0.97 cm, SD 
0.11 cm).  The van Herk margin formula (VHMF) suggests a margin of 0.96 cm. This value only 
matched one sample using the optimized margin method, all others were lower. The specific 
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plan which matched the VHMF produced 99.8% coverage probability to the CTV for the margin 270 
plan and 99.6% coverage for the PTP plan. The margin suggested by the VHMF being larger than 
the margin required using iterative margin expansion is consistent with the results shown by 
Gordon et al.7 In that work, it was shown that the volume receiving the prescription dose, 
termed the treated volume in ICRU nomenclature,  is larger than the CTV‐to‐PTV margin, 
therefore yields  greater coverage.  275 
DVCMs and DVCDMs for the CTV, bladder, rectum and femur for Patient 1 are shown in 
Figure 6.  The trends in the data found for Patient 1 are typical of those for other patients.  For 
the CTV, the DVCMs are similar, but not identical.  Similarity is expected since the margin‐based 
plan optimization is adjusted to provide the same coverage as the PTP plan.  The CTV D98 dose‐
volume objective has on average 90% coverage probability.  Above D98, dose coverage rapidly 280 
drops falling off towards the D2 objective, with 45% at D2.  The rapid dose fall‐off results from 
the upper and lower optimization DVH objectives which are set to achieve a uniform CTV dose. 
The DVCDM, which compares the PTP and margin‐based DVCMs, shows a difference band with 
a width of ~1 Gy.  These minor differences are expected since, although the margin‐based 
coverage was optimized to be equivalent, even if the margin and PTP‐based coverage values 285 
are equivalent at D98, coverage diverges at other dose values since the PTP and margin‐based 
dose distributions differ.  Although the primary convergence criterion requires coverage 
probability agreement within 0.5%, for some patients, target coverage differs by up to 8%.  In 
the margin‐based plans, target coverage can be very sensitive to slight changes in margin, thus 
it was not feasible to achieve exactly the same coverage as in the PTP plans. However, slight 290 
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differences in target coverage were evaluated by physicians in their assessment of plans, and 
were judged not to be clinically significant.    
Larger differences in DVCMs are observed for the OARs as shown in Figure 6.  To 
understand the clinical meaning of the differences observed, it is it is useful to sub‐divide OAR 
DVCMs into 3 regions as shown in Figure 7:  Region A is completely below the plan optimization 295 
objectives.  Differences in region A can be considered to be unimportant as they are below the 
plan objectives.  If doses in region A are deemed to be important for planning, an objective 
should be added to control dose in these areas, resulting in the point being moved to either 
region B or C.  Region B is completely above the plan optimization objectives and is a clinically 
important region since this is where the optimizer failed to reduce the dose below the plan 300 
objectives.  Region C is the intermediate region near the plan objectives, and is also clinically 
important since it demonstrates the objective function tradeoffs as the plan optimizer finds a 
solution.  
The general trends seen for Patient 1 are evident for all patients:  when an OAR dose is 
near the plan objectives, PTP reduces dose coverage in that region.  This shows as blue in the 305 
DVCDM. However, PTP increases dose coverage at dose‐volume regions well below the 
objective values.  This shows as red in the DVCDM. From the methods used in this study, it 
cannot be determined if the increased OAR volumes receiving low doses is inherent to PTP or if 
adding dose‐volume objectives for the lower volumes would push the dose to unspecified 
tissues.  PTP shows higher coverage – the probability of the DVH curve exceeding the dose for a 310 
given volume – for all OARs in region A well below the planning objectives. For the bladder, 
neither method shows coverage in region B, while both methods show coverage in region C. 
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PTP plans showed higher bladder coverage in region C for 9 out of 28 patients, while 5 patients 
showed higher coverage in the margin‐based plans. For the rectum, none of the PTP plans 
showed coverage in region B while 7 out of 28 patients showed coverage in the margin‐based 315 
plans. Margin‐based plans showed higher rectal coverage in region C for 20 out of 28 patients 
while PTP plans show rectal coverage in region C for only one patient. For the femur, neither 
method shows coverage in region B. Femoral coverage is very low in both methods in region C. 
For the left femur a small dose tail extends out to the 5000cGy max dose objective in 21 out of 
28 PTP plans, and 12 out of 28 for margin‐based plans. For the right femur the tail reached the 320 
objective in 22 out of 28 PTP plans, and 12 out of 28 margin‐based plans. 
  The average coverage probability for each structure is shown in Table 3. Target coverage 
probability is generally the same for each patient due to the design of the study. The average 
difference in coverage probability between PTP and margin plans is 0.7% +/‐ 2.7%. The 
difference is not significant (p=0.17) with a paired t‐test.  325 
For organs at risk, the average coverage probability over all patients for PTP plans 
decreased 17% for the rectum D35<65Gy objective (p=0.010) as compared to margin‐based 
plans, decreased 23% for the rectum D25<70Gy objective (p<0.0001) and decreased 27% for the 
rectum D15<75Gy objective (p<0.0001).  The bladder coverage changes are smaller, with PTP 
resulting in D50<65Gy increased by 2% ( p=0.0005), D35<70Gy increased by 3% (p=0.156), 330 
D15<80Gy decreased by 6% (p=0.0146), left femur 50Gy max increased by 4% (p=0.0078) and 
right femur increased by 6% (p=0.0024) when compared to margin‐based plans.  Coverage for 
other objectives did not change significantly. 
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Discussion	
This study assumes random and systematic setup errors with standard deviations equal 335 
to 3 mm in each direction to simulate setup uncertainties.  These numbers are typical of setup 
error values reported in the literature for (implanted marker‐based) image alignment.4, 5, 13, 18, 25, 
26  For the comparison purposes of this study, matching the setup‐error to the clinical setup 
error is not required.  While the general PTP method described in this paper allows non‐
normally distributed errors, unequal errors in each direction, and for tissue deformation, 340 
margin‐based methods typically are not based on these assumptions.  Standard margin 
formulas3‐6 assume normally distributed setup errors, and clinically, margins are typically 
chosen to be uniform in all directions around a structure, with occasional trimming to avoid 
nearby organs at risk.  Use of normally distributed errors with the same standard deviation in 
each direction for PTP, while simplistic, realistically mimics the assumptions made in margin 345 
based planning, but disregards the flexibility of PTP to address non‐normal motion or tissue 
deformations.  Thus, bias introduced by assuming uniform and normally distributed errors will 
be in favor of the margin based approach.  Nonetheless, the results demonstrate the 
advantages of PTP even when the assumptions of margin‐based planning are followed.   
In the plan assessment stage, both static DVHs and PDVHs are used in this work. A 350 
comparison of static DVH and PDVH curves are displayed in Figure 5. A static DVH represents a 
single patient setup.  To ensure setup uncertainties are considered in planning, PTV DVHs are 
used to represent the DVH of the CTV.1  For OARs, ideally PRVs are used to represent likely dose 
distributions to underlying structures.  However, often PRVs are not used in planning, resulting 
in overly optimistic dose representation.  A PDVH curve represents the DVH for a specified 355 
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coverage probability. For the curves demonstrated in this work, the probability of CTV doses 
exceeding the PDVH is 95% and the probability of the dose to the critical structures being lower 
than the PDVH is 95%. Therefore, it is expected that in 95% of cases, the plan will perform 
better than the displayed curves.   
Comparison of DVHs and PDVHs (e.g. Figure 5 and Figure 8) show that although margin‐360 
based plans seemingly meet or nearly meet the OAR optimization criteria when evaluated 
based on static DVHs, PDVH evaluation reveals a strong likelihood that the optimization criteria 
will be exceeded.  Independent of the planning method, it would be prudent to provide 
physicians with the PDVH information for plan evaluation to allow incorporation of this 
information in the plan approval decision making process.  Plans which have a significant 365 
probability of overdosing OARs should be rejected. 
  To directly compare margin‐based planning to PTP, patient specific coverage optimized 
margins were used in this study.  In routine clinical practice, it is more common to use the same 
margin for each patient.   An accepted method would be to use the van Herk margin 
formulation to determine the margin, which, for the setup errors assumed in this study would 370 
have yielded a margin of approximately 1 cm. Plans produced with a 1 cm margin would have 
resulted in both higher target coverage probability and an increase in dose to nearby local 
structures (an increased coverage probability for critical structures) compared to the optimized 
margins used in this study. 
Due to conflicting planning goals produced by PTV and PRV overlap structures and other 375 
considerations, PRV margins are often not used in conjunction with PTV‐based planning.  The 
1 cm OAR‐to‐PRV margins used in this study therefore result in a level of OAR protection often 
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not afforded by PTV‐based planning.  If the margin‐based portion of this study would be 
repeated with zero OAR‐to‐PRV margins, OAR‐to‐PRV margins equal to the CTV‐to‐PTV margins, 
or any value less than 1 cm, the resultant optimized dose distributions would increase OAR 380 
doses, further exemplifying the advantages of PTP.   
  The work in this study required a great amount of computational resources. An average 
optimization including weight adjustment took nearly two days on a single 2.83 GHz processor. 
This is unrealistic in a clinical scenario. Fortunately, the methods proposed here can be easily 
parallelized. Computation of gradients and objective functions for different shifts are 385 
independent of each other. With a multiple processor machine or cluster, computation of shifts 
could be spread to multiple CPUs. Further enhancements and optimization of the code may 
also reduce the time required. 
Conclusions	
For the same CTV coverage probability, PTP results in a reduced rectal dose. DVCDMs 390 
show that dose is decreased in the neighborhood of the optimization constraints, while dose is 
increased in unconstrained areas. Physician assessment indicates that PTP plans are preferred 
by all physicians and assessment methods 71% of the time, while optimized margin‐based plans 
are preferred by all physicians and assessment methods 7% of the time. Significant reductions 
in coverage of the rectal objectives were achieved (16‐27%) though small increases in coverage 395 
of the bladder and femurs were observed (2‐6%) 
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Figures	
Table 1: Planning objectives according to RTOG‐0126 with initial weights used in optimization 
Structure Type  Dose (cGy) Volume (%) Weight
Target Min DVH 7920 98 100
Target Max DVH 8470 2 90
Rectum Max DVH 6000 50 80
Rectum Max DVH 6500 35 80
Rectum Max DVH 7000 25 80
Rectum Max DVH 7500 15 80
Rectum Max Dose 8470 80
Bladder Max DVH 6500 50 80
Bladder Max DVH 7000 35 80
Bladder Max DVH 7500 25 80
Bladder Max DVH 8000 15 80
Bladder Max Dose 8470 80
Left Femur Max DVH 3500 50 20
Left Femur Max Dose 5000 20
Right Femur Max DVH 3500 50 20
Right Femur Max Dose 5000 20
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Table 2: Physician assessment of PTP and margin‐based plans. Preferred plan is indicated for each physician using Probability 480 
Dose Volume Histograms or static Dose‐Volume Histograms. 
PDVH  Static DVH 
Patient  Physician 1  Physician 2  Physician 1  Physician 2 
1  PTP  PTP  PTP  PTP 
2  PTP  PTP  PTP  PTP 
3  PTP  PTP  PTP  PTP 
4  PTP  PTP  PTP  PTP 
5  PTP  PTP  PTP  PTP 
6  PTP  PTP  PTP  PTP 
7  PTP  PTP  PTP  PTP 
8  PTP  PTP  PTP  PTP 
9  PTP  PTP  PTP  PTP 
10  Margin  Margin  Margin  Margin 
11  PTP  PTP  PTP  PTP 
12  Margin  Margin  Margin  PTP 
13  PTP  PTP  PTP  PTP 
14  PTP  PTP  PTP  PTP 
15  PTP  PTP  PTP  PTP 
16  Margin  PTP  PTP  PTP 
17  PTP  PTP  PTP  PTP 
18  PTP  PTP  PTP  PTP 
19  PTP  PTP  PTP  PTP 
20  Margin  PTP  PTP  PTP 
21  PTP  PTP  PTP  Margin 
22  PTP  PTP  PTP  PTP 
23  PTP  PTP  PTP  PTP 
24  PTP  PTP  PTP  PTP 
25  PTP  PTP  PTP  PTP 
26  Margin  Margin  Margin  Margin 
28  Margin  PTP  PTP  Margin 
30  Margin  Margin  PTP  PTP    
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Table 3: Coverage for PTP and Margin plans at planning objectives. Change represents coverage of PTP plan less coverage of 
margin plan. Significance is a result of a 2‐sided paired t‐test. 
Structure  Volume (%)  Dose (cGy)  PTP Margin Change p 
BLADDER   50  6500 3 1 2 0.0005
BLADDER   35  7000 10 6 3 0.0156
BLADDER   25  7500 10 11 ‐1 0.7609
BLADDER   15  8000 5 11 ‐6 0.0146
BLADDER   0  8470 37 22 14 0.1084
CTV   98  7920 90 91 ‐1 0.2292
CTV   2  8470 45 32 12 0.2328
FEMUR_LT   50  3500 0 0 0 n/a 
FEMUR_LT   0  5000 5 1 4 0.0078
FEMUR_RT   50  3500 0 0 0 n/a 
FEMUR_RT   0  5000 6 0 6 0.0024
RECTUM   50  6000 1 6 ‐5 0.0962
RECTUM   35  6500 9 26 ‐17 0.0010
RECTUM   25  7000 18 41 ‐23 0.0000
RECTUM   15  7500 28 55 ‐27 0.0000
RECTUM   0  8470 19 10 9 0.1794
 485 
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Figure 1: Flow chart describing overall comparison process  
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Figure 2: Process for generating the final optimized PTP plan
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 490 
Figure 3: Process for generating the initial PTP plan.  nSys is the number of systematic shifts used during the PTP optimization 
process.
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Figure 4: PTP Process to generate an optimized plan accounting for systematic uncertainty. F is the total objective score, G is 
the total gradient matrix containing the first derivative of the objective function Gi for each voxel i. Fs is the objective 495 
function score for shift s 
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Figure 5: Static DVH and PDVH curves for the CTV, bladder, rectum, left femur and right femur for the PTP generated for 
Patient 1. Solid lines represent PDVH curves and dashed lines represent static DVH. Objectives used during optimization are 
given as triangles.  500 
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Figure 6: Dose‐volume coverage maps (DVCM) and dose‐volume coverage difference maps (DVCDM) for the CTV, bladder, 
rectum and femur for Patient 1.  The DVCM indicates the probability that the dose‐volume level is achieved in a given 
treatment course. Triangles on the DVCM  indicate the dose‐volume planning objectives used during plan optimization.  The 505 
DVCDM compares the PTP and the margin‐based plans.  Values less than zero (blue regions)  indicate lower doses by the PTP 
plan compared with the margin plan.  Values greater than zero (red regions) indicate higher doses by the PTP plan. 
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Figure 7: Regions of a DVCM. Region A is below the plan objectives, Region B is above the plan objectives and Region C is the 
intermediate area near the plan objectives.    510 
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Figure 8:  (A) Probability Dose‐Volume Histogram for the 95% percentile DVH for the CTV and 5% DVH for the Bladder, 
Rectum and Femurs for PTP and margin‐based plans. (B) Static Dose‐Volume Histograms for the CTV, bladder, rectum, left 
femur and right femur for PTP and margin‐based plans. Solid lines represent PDVH curves for the PTP plan and dashed lines 515 
represent the margin‐based plan. Objectives used during optimization are given as triangles.   
 
 
A) PDVH  B) Static DVH 
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Appendix III 
Dose-Volume Coverage Maps for all patients used in study. For each patient, DVCMs for 
PTP plans and margin-based plans are displayed with the Dose-Volume Coverage Difference 
Map. Maps for the CTV, bladder, rectum, left femur and right femur are presented. For DVCMs, 
values of 1 indicate 100% coverage probability of the dose-volume point for a given structure for 
all simulated offsets. Values of 0 indicate zero coverage probability of the dose-volume point for 
a given structure for any simulated offset. For DVCDMs, positive values indicate greater 
coverage probability by the PTP plan, while negative values indicate greater coverage 
probability by the margin-based plan.
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Appendix IV: Static Dose-Volume Histograms 
Static Dose-Volume Histogram plots for all patients used in this study. For each patient, a 
DVH curve is plotted for CTV, rectum, bladder, left and right femur. Solid lines indicate PTP 
plans and dashed lines indicate margin-based plans.
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Appendix V: Probability Dose-Volume Histograms 
Probabilistic Dose-Volume Histogram plots for all patients used in this study. For each 
patient, a PDVH curve is plotted for CTV, rectum, bladder, left and right femur. Solid lines 
indicate PTP plans and dashed lines indicate margin-based plans. For target structures, the 
realized DVH curve will be above the PDVH curve 95% of the time. For OAR structures, the 
realized DVH curve will be below the PDVH curve 95% of the time.
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